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1 ABSTRACT 
Mortality from coronary heart disease (CHD) among the working-age population 
has declined by 70% during the past 50 years in Finland. Factors contributing to 
this development include both advances in health policy and the improvement of 
medical care. Despite this favourable trend, cardiovascular disease (CVD), 
especially ischaemic heart disease, is still the leading cause of death among the 
working-age male population in Finland. One of the substantial risk factors for 
CVD and type 2 diabetes is obesity, predominantly abdominal – that is the 
accumulation of fat in the visceral adipose tissue. When the subcutaneous adipose 
tissue's ability to store fat is exceeded, the excess fat accumulates in the visceral 
adipose tissue and ectopic depositions in organs, such as skeletal muscles, liver, 
pancreas, and heart. This aberrant fat accumulation strongly correlates with an 
adverse cardiometabolic profile.  
We studied the association between visceral adiposity and cardiac steatosis in 70 
non-diabetic obese middle-aged men. The amount of visceral adipose tissue, 
abdominal subcutaneous tissue and epicardial and pericardial fat depositions was 
measured by magnetic resonance imaging. Cardiac steatosis correlated with the 
amount of abdominal subcutaneous fat tissue and visceral adiposity; the correlation 
was stronger with visceral adiposity. Furthermore, of all the cardiometabolic risk 
factors measured, WC correlated strongest with visceral adiposity as well as 
epicardial and pericardial fat.  
WC is an indirect measure, but it is considered to be a reliable measure of visceral 
adiposity. Thus, it can serve as a tentative means when assessing the risk for CVD 
and type 2 diabetes. To study the predictive value of WC to assess the risk for CVD 
and type 2 diabetes in middle-aged men, we used data from 200 men from a 
community-based screening programme in the city of Helsinki. Our results show 
that a cut-off point for a WC of ≥ 94 cm identifies those with increased risk for 
CVD and/or type 2 diabetes with a sensitivity of 84.4% and specificity of 78.2%.  
Yearly, from 2006 onwards, all men aged 40 living in Helsinki have been invited to 
a CVD risk evaluation and health counselling visit at their local healthcare centre. 
Men who were found to be at high risk received lifestyle counselling aiming at risk 
reduction. We conducted two prospective follow-up studies among the men who 
were at high risk in the year 2006 screening. In the first study, our aim was to 
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determine whether the impact of lifestyle counselling on health behaviour and total 
CVD risk during the two years of follow-up depended on educational attainment. 
In 2008, a total of 430 initially high-risk men were identified and invited to a 
follow-up visit; 200 participated. Subjects were categorised into three groups 
according to their educational attainment: low (≤ 9 years), middle (10 to 12 years) 
and high (≥ 13 years). We observed a positive trend in lifestyles in all three groups. 
In the low educational attainment group, the change in lifestyle did not lead to a 
significant reduction in the overall risk for CVD, whereas the risk reduction was 
statistically significant in the two higher educational attainment groups during 
follow-up. 
In our second prospective study, we aimed to determine whether the continuation 
of risk communication would lead to and sustain lifestyle changes and maintain the 
possibly achieved lower CVD risk during the five-year follow-up. In 2011, a total 
of 389 initially high-risk men were identified and invited to a follow-up visit; of 
these, 159 participated. We observed that the participants’ self-reported lifestyles 
improved regardless of the continuation of risk communication, while the overall 
risk for CVD improved only among those who were continuing risk 
communication during the five-year follow-up. 
If lifestyle behaviour has not been optimal during early adulthood, a person may 
have been exposed to one or more CVD risk factors before reaching middle age. 
Often, an easily recognisable indication of such exposure is abdominal obesity. In 
everyday practice in primary healthcare, abdominal obesity and a low level of 
education should trigger a comprehensive risk evaluation and, when appropriate, an 
offer of health counselling. Achieving sustainable lifestyle changes and risk 
reduction requires ongoing risk communication between parties.  
12 
 
2 TIIVISTELMÄ  
Työikäisen väestön sepelvaltimotautikuolleisuus on 50 viime vuoden aikana 
vähentynyt Suomessa 70%. Myönteiseen kehitykseen on vaikuttanut tietoinen 
pyrkimys tupakoinnin vähentämiseen sekä elintapojen kautta väestön 
kolesterolipitoisuuksien pienentämiseen ja verenpainetasojen madaltamiseen. 
Nämä muutokset selittävät yli puolet kuolleisuuden vähentymisestä, hoitojen 
tehostuminen sekä kehitys loput. Huolimatta myönteisestä kehityksestä sydän- ja 
verisuonitaudit ovat edelleen yleisin työikäisten miesten kuolinsyy Suomessa.  
Yksi merkittävä sydän- ja verisuonisairauksille ja tyypin 2 diabetekselle altistava 
riskitekijä on lihavuus, erityisesti vyötärölihavuus, joka heijastaa ylimääräisen 
rasvan kertymistä vatsaonteloon. Kun ihonalaisen rasvakudoksen kyky varastoida 
rasvaa ylittyy, vatsaonteloon kertyvän rasvan lisäksi rasvaa varastoituu 
luustolihaksiin, maksaan, haimaan ja sydämeen. Tämä ei-toivottu sisäelimiin 
kertyvä rasva korreloi vahvasti haitallisen metabolisen riskiprofiilin kanssa. 
Selvitimme tutkimuksessamme diabetesta sairastamattomien lihavien miesten 
sydämen rasvoittumisen ja vatsaonteloon kertyneen rasvan määrän suhdetta sydän- 
ja verisuonitautiriskitekijöihin 
Rasvan määrä vatsaontelossa, vatsan alueen ihonalaisessa kudoksessa ja sydämessä 
mitattiin magneettikuvauksella. Sydämen rasvoittuminen korreloi sekä vatsan 
alueen ihonalaisen rasvakudoksen että vatsaonteloon kertyneen rasvan määrään, 
voimakkaammin jälkimmäiseen. Kaikista mitatuista metabolisista riskitekijöistä 
vyötärönympärys korreloi voimakkaimmin vatsaontelon sisäisen rasvan määrään ja 
sydämen rasvoittumiseen. 
Vyötärönympärysmitta on epäsuora, mutta luotettavaksi osoitettu vatsaonteloon 
kertyneen rasvan mittari. Sitä voidaan käyttää alustavana keinona arvioitaessa 
riskiä sairastua sydän- ja verisuonitauteihin sekä tyypin 2 diabetekseen.  
Toisessa tutkimuksessamme selvitimme vyötärönympärysmitan kykyä löytää 
valikoimattomasta keski-ikäisten miesten joukosta miehet, joiden riski sairastua 
sydän- ja verisuonitauteihin sekä tyypin 2 diabetekseen oli suurentunut. 
Aineistomme koostui kahdestasadasta keski-ikäisestä helsinkiläismiehestä, jotka 
olivat osallistuneet Helsingin kaupungin terveyskeskuksen järjestämään 
riskiseulontaan. Tulokset osoittivat, että vyötärönympärysmitan raja-arvo ≥94 cm 
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erottaa osallistujien joukosta ne, joiden riski sairastua sydän- ja verisuonitauteihin 
tai tyypin 2 diabetekseen on riskiprofiilin perusteella lisääntynyt. Kyseistä raja-
arvoa käyttämällä menetelmän herkkyys oli 84,4% ja tarkkuus 78,2%. 
Vuodesta 2006 alkaen on vuosittain kutsuttu kaikki Helsingissä asuvat kyseisenä 
kalenterivuonna 40 vuotta täyttävät miehet sydän- ja verisuonitautiriskien 
arviointiin ja terveysneuvontaan paikalliseen terveyskeskukseen. Miehille, joiden 
riskin todetaan suurentuneen, annetaan elintapaneuvontaa, jonka tavoitteena on 
riskin pienentäminen. Toteutimme kaksi seurantatutkimusta miehillä, joilla vuoden 
2006 seulonnassa todettiin lisääntynyt sydän- ja verisuonitautien riski. 
Ensimmäisen tutkimuksen tavoitteena oli selvittää elintapaneuvonnan vaikutusta 
sydän- ja verisuonitautien kokonaisriskiin kahden vuoden seurannassa niin, että 
osallistujien koulutustaso otettiin huomioon. Vuonna 2008 miehistä, joiden riski oli 
todettu suureksi, tavoitettiin 430. Heidät kutsuttiin seurantakäynnille, ja 200 
noudatti kutsua. Osallistujista muodostettiin koulutustason mukaan kolme ryhmää. 
Elintavat muuttuivat suotuisammiksi kaikissa kolmessa ryhmässä. Alimman 
koulutustason ryhmässä elintapojen muutokset seuranta-aikana eivät kuitenkaan 
johtaneet merkitsevään sydän- ja verisuonitautien kokonaisriskin pienenemiseen 
toisin kuin kahdessa korkeamman koulutustason ryhmässä. 
Toisessa seurantatutkimuksessa selvitimme viiden vuoden seuranta-aikana 
omaehtoisesti toistettujen riskinarviointitapaamisten vaikutusta pienemmän riskin 
saavuttamiseen ja ylläpitoon. Vuonna 2011 miehistä, joiden riski oli seulonnassa 
alun perin todettu suureksi, tavoitettiin 389. Heidät kutsuttiin seurantakäynnille, ja 
kutsua noudatti 159 miestä. Tulokset osoittivat, että elintavat olivat muuttuneet 
suotuisaan suuntaa riippumatta siitä, oliko riskejä arvioitu uudelleen seuranta-
aikana. Muutos oli tilastollisesti merkitsevä. Kuitenkin vain seuranta-aikana 
uudelleen riskinarvioinnissa käyneiden sydän- ja verisuonitautiriski pieneni. 
Altistuminen epäedullisten elintapojen vaikutuksille alkaa jo lapsuudessa ja jatkuu 
aikuisikään, jolloin viimeistään todetaan muutokset myös biologisissa 
riskitekijöissä. Usein ensimmäinen ulkoinen merkki altistumisesta voi olla 
keskivartalolihavuus. Päivittäisessä vastaanottotyössä olisi tärkeää käynnistää 
laajempi sydän- ja verisuonisairauksien riskikartoitus kaikille keskivartalolihaville 
sekä sosioekonomiselta asemaltaan heikommille. Samalla olisi tärkeää tukea 
riskienhallintaakin. Saavutettujen elintapamuutosten ja pienemmän riskin 
ylläpitäminen edellyttää palveluiden tuottajien ja käyttäjien yhteydenpidon 
jatkuvuutta. 
14 
 
3 INTRODUCTION 
Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Almost 
one-third (31%) of all deaths among men younger than 65 in Europe were caused 
by CVD according to WHO´s Mortality Database update in February 2014 (1). The 
Global Burden of Disease Study 2010 identified the top-eight risk factors 
contributing to the Global Burden of Disease. In Europe, these are, in descending 
order: tobacco smoking, high blood pressure (BP), high body mass index (BMI), 
alcohol use, physical inactivity, high fasting plasma glucose, a diet low in fruit and 
high total cholesterol (2). The European Guidelines on CVD prevention in clinical 
practice contain the same behavioural risk factors (3). The four main behavioural 
risk factors for CVD identified by the World Health Organization (WHO) are 
tobacco smoking, an unhealthy diet, physical inactivity and the harmful use of 
alcohol (4). A healthy lifestyle adopted in early adulthood and sustained throughout 
life protects individuals from CVD (5). However, lifestyle changes in middle age 
still have the potential to reduce the risk of CVD. In a cohort study of adults aged 
45 to 64 who engaged in a healthy lifestyle (i.e. diet high in fruits and vegetables, 
regular exercise, BMI 18.5–29.9 kg/m2 and not smoking) CVD events and 
mortality were reduced significantly in the four-year follow-up compared to people 
with less healthy lifestyles (6). In the U.S. Health Professionals Follow-up Study, 
men who adopted at least two new healthy lifestyle factors during the follow-up 
significantly decreased their relative risk of coronary heart disease (CHD) 
compared with men who did not change their unhealthy lifestyle (7). The preventive 
potential of modifiable behavioural risk factors in the middle-aged and older 
population is considerable. The cross-sectional population-based survey of adults 
aged 40 to 79 shows that only 16% of the study’s population was free from 
behavioural risk factors (i.e. daily smoking, physical inactivity, low fruit intake, 
high alcohol consumption and obesity), while 45% had at least two of these 
behavioural risk factors (8).  
Primary healthcare has a significant role in supporting population strategies to 
reduce the risk for CVD by promoting a healthy lifestyle in the general public. As 
primary healthcare provides most public health services, it can identify those who 
are at high risk and implement preventive measures. There are clinical guidelines to 
facilitate the assessment and management of CVD risk in primary healthcare. 
According to these guidelines, expert organisations recommend beginning 
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systematic total CVD risk assessments in men at age 40 and in women at age 50 
(3,9). However, it has been shown that there are shortcomings in the implementation 
of guidelines in general practice. In the primary prevention of a high-risk 
asymptomatic population, risk factors remain uncontrolled for a large proportion 
(10), and healthier lifestyle promotions have not progressed properly. Consequently, 
risk factor targets were poorly achieved (11,12). Although the majority of physicians 
support the use of guidelines, only half apply them in their everyday practice (13). 
Accordingly, the objective of this thesis is to evaluate whether the screening of 
CVD risk factors among men age 40 combined with lifestyle counselling for those 
at high risk is beneficial from a long-term risk management perspective. 
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4 REVIEW OF THE LITERATURE 
‘The scale and pattern of disease reflect the way that people live and their social, 
economic, and environmental circumstances, and all of these can change quickly’. 
On page 35 of The Strategy of Preventive Medicine by Geoffrey Rose (1992). 
4.1 Cardiovascular disease 
Cardiovascular disease (CVD) is defined as a group of disorders of the heart and 
blood vessels, including CHD, cerebrovascular disease, elevated BP, peripheral 
artery disease, rheumatic heart disease, congenital heart disease and heart failure.  
CVD causes more deaths globally than any other non-communicable disease group. 
CHD and stroke are the major components of CVD. The World Health 
Organization (WHO) has estimated that the total number of deaths from CVD was 
17.7 million in 2015 globally. These include CHD being responsible for 7.4 million 
deaths and stroke being responsible for 6.7 million deaths (4). The corresponding 
figures for Europe were 4 million in total, 1.8 million from CHD and 1 million 
from stoke, respectively (14). There are striking differences in age-adjusted CVD 
mortality rates between European countries; the highest mortality rates are seen in 
Eastern Europe. They are almost tenfold higher than the lowest rate in Western 
Europe (14). In Finland, age-standardised CHD mortality has decreased 
continuously over the past 40 years, a trend that continued in 2015. During the 
same time period, the median age of people who died of CHD increased from 65 
years to 79 years among men and from 73 years to 87 years among women. In 
1971, nearly four out of ten of those who died of CHD were of working age, while 
in 2015, the corresponding figure was one out of ten (15). 
4.2 Historical perspectives on preventive cardiology  
The epidemiological approach to CVD can be considered to have begun in the 
1940s. Among the first studies was a prospective study of professional men in 
Minnesota. The 15-year follow-up indicated an association between CHD mortality 
and total cholesterol (16). This research was followed by the Seven Countries Study, 
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another prospective study, in which the 25-year follow-up results confirmed the 
association between total cholesterol and CHD (17). The results also showed a 
positive association between BP and CHD (18). The results from the U.S. Railroad 
cohort of the Seven Countries Study during a 40-year period demonstrated 
significant associations between CVD and smoking, systolic blood pressure (SBP) 
and serum cholesterol (19). Importantly, the Seven Countries Study revealed this 
relationship was not dependent on culture. Simultaneously, the Framingham Heart 
Study (FHS) provided further evidence on the importance of BP, cholesterol and 
cigarette smoking in the development of CHD (20,21,22). The Whitehall study (23) 
increased the general knowledge of CVD risk factors, myocardial ischaemia and 
CHD death. Based on the observation that the number of risk factors and their 
simultaneous occurrence is directly related to the incidence of CHD, the 
investigators of the FHS were the first to introduce the concept of a global risk 
assessment for CHD (24,25). There are several other important epidemiological 
studies that have been conducted over the past 70 years that have contributed to 
establishing the practices of preventive cardiology based on risk factors and risk 
assessment. The largest of these studies was The Monica Project (26), the 
publications of which expose the trends of CHD risk factors in various populations 
and the contributions of these trends to event rates and CHD mortality. The 
Interheart study (27), conducted globally, showed that the same large pattern of risk 
factors was consistently associated with myocardial infarction worldwide in all 
ethnic groups and in both sexes.  
4.3 Risk factors for CVD 
There is a broad consensus concerning the major risk factors for CVD. Risk factors 
are classified as modifiable and non-modifiable. Non-modifiable risk factors 
include sex, age, race and family history of CVD. Major modifiable risk factors 
include physical inactivity, tobacco exposure, unhealthy diet, obesity and harmful 
use of alcohol, high BP, dyslipidaemia and type 2 diabetes (28). Besides modifiable 
risk factors, other risk factors include low socioeconomic status, psychosocial 
stress, depression and anxiety.  
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4.4 Behavioural risk factors 
During recent decades, evidence from epidemiological research has shown the 
importance of lifestyle factors concerning the development of diseases. Regarding 
CVD, the main contributing behaviours are harmful use of alcohol, tobacco 
smoking, unhealthy diet and physical inactivity. 
4.4.1 Diet 
A diet rich in saturated fat, trans-fats and salt, and low in fruits, vegetables and fish 
is linked to increased cardiovascular risk (29). The Seven Countries Study was the 
first large cohort study that investigated the association between diet and CVD. 
Food consumption patterns varied highly between the study populations in the 
1960s (30). Twenty-five years of follow-up showed the diversity of dietary patterns 
had markedly different consequences respecting CHD mortality. A diet low in 
animal and dairy products and rich in plant food seemed to be protective against 
CHD on the population level (31). A dietary pattern characteristic of Greece and 
other parts of the Mediterranean region was called the Mediterranean diet (31). The 
Mediterranean diet is characterised by the high intake of plant food and olive oil; 
moderate intake of fish and poultry; low intake of dairy products, red meats, 
processed meats and sweets; and wine consumed in moderation with meals (32). In 
prospective population-based research with a median follow-up of 44 months, 
higher degree adherence to a Mediterranean diet was associated with significantly 
lower total mortality, mortality from CHD and mortality from cancer, hazard ratios 
being 0.75 (95% CI 0.64–0.87), 0.67 (95% CI 0.47–0.94) and 0.76 (95% CI 0.59–
0.98), respectively (33). A meta-analysis of 34 prospective cohort studies including 
over 4 million people demonstrated that a two-point increase in the adherence to 
the Mediterranean diet resulted in an 8% reduction in overall mortality, a 10% 
reduction in mortality and incidence of CVD, a 6% reduction in mortality and 
incidence of cancer and a 13% reduction in neurodegenerative disease (34). In work 
based on the Epic–Norfolk prospective cohort, a higher adherence to the 
Mediterranean-style diet turned out to be effective in reducing CVD incidence and 
mortality, even beyond the Mediterranean region (35). In a randomised secondary 
prevention trial (Lyon Diet Heart Study), the Mediterranean diet (enriched with 
alpha-linolenic acid) proved to be more effective than the usually recommended 
post-infarct diet to prevent recurrent cardiac events. During a mean follow-up of 27 
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months after a first myocardial infarction, the risk ratio for the composite outcomes 
including cardiac death and non-fatal myocardial infarction was 0.27 (95% CI 
0.12–0.59), indicating a 73% risk reduction in the intervention group compared to 
the control group (36). After a mean follow-up of 46 months, authors confirmed that 
the protective effect of the Mediterranean diet was maintained as a risk ratio, for 
the composite outcome was 0.28 (95% CI 0.15–0.53) (37). In a primary prevention 
study (Predimed study), subjects with high cardiovascular risk but no CVD at 
enrolment were randomly assigned to one of three groups: a Mediterranean diet 
supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with 
mixed nuts and a control diet (participants in control group was advised to reduce 
dietary fat) (38). After a median follow-up of 4.8 years, the findings indicated that 
the Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts 
reduced the incidence of major cardiovascular events (myocardial infarction, stroke 
or death from cardiovascular causes) by 30% compared to the control diet. 
There is an ongoing large, randomised CVD primary prevention trial (Predimed-
Plus) that is focusing on multiple lifestyle factors: the Mediterranean diet, physical 
activity and weight control (39). The study’s investigators have reported the 
effectiveness of an intensive lifestyle intervention on weight-loss and 
cardiovascular risk factors in 626 overweight/obese adults with metabolic 
syndrome aged 55–75 years (n = 626). The lifestyle intervention is based upon an 
energy-restricted Mediterranean diet, physical activity promotion and behavioural 
support. The intervention group includes 327 participants, with 299 in the control 
group, respectively. At the 12 months’ follow-up, the average weight loss in the 
intervention group was 3.2 kg, and in the control group, 0.7 kg. A weight loss ≥ 5% 
was achieved by 33.7% of the participants in the intervention group and by 11.9% 
in the control group. The improvement of cardiovascular risk factors was greater in 
the intervention group compared to the control group (40).  
4.4.2 Physical activity 
Epidemiological studies have shown that physical inactivity is an independent risk 
factor for both CVD and all-cause mortality (41,42,43). The main types of physical 
activities that have been focused upon in studies regarding this topic are work-
related, commuting and leisure-time physical activities (LTPA). Morris and 
colleagues researched bus drivers in the 1950s (44), and Paffenbarger and colleagues 
investigated dockworkers in the 1970s (45), all demonstrating that physical activity 
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at work has a protective effect against CHD mortality. Supporting findings were 
obtained in several other studies examining the relationship of CHD to physical 
activity, whether work or leisure. Such studies were summarised in a review article 
published in 1987 (46), and in a meta-analysis published in 1990 (47). Both of these 
reports conclude that the literature at that time revealed consistent evidence of an 
inverse association between physical activity and the incidence of CHD. 
Accumulated evidence led the American Heart Association in 1992 to identify 
physical inactivity as a risk factor for CVD (48). In 1996, the U.S. Surgeon General 
highlighted the health benefits of moderate daily physical activity for both sexes 
and all ages (49). In 2008, the U.S. Department of Health and Human Services 
(HHS) released their Physical Activity Guidelines for Americans (50). In 2010, the 
WHO followed this publication with their Global Recommendations on Physical 
Activity on Health’ (51). Both organisations recommend a minimum of 150 minutes 
a week of moderate-intensity physical activity or 75 minutes a week of aerobic 
vigorous-intensity physical activity. Even greater health benefits can be achieved 
by increasing the amount of weekly physical activity. The recommendation has 
since been widely adopted in national recommendations around the world. In 
‘European Guidelines on CVD Prevention in Clinical Practice’, the 
recommendations for physical activity are consistent with the abovementioned 
bodies (3). A meta-analysis published in 2011 reported that subjects who maintained 
the level of 150 minutes per week of moderate-intensity LTPA have a relative risk 
for CHD of 0.86 (95% CI 0.77–0.96) compared to sedentary subjects. Of those who 
maintained a level of 300 minutes per week of moderate-intensity LTPA, the 
corresponding relative risk was 0.80 (95% CI 0.74–0.88 (52). The HHS released 
their second edition of Physical Activity Guidelines for Americans in 2018. The 
recommendation for weekly moderate and vigorous intensity of physical activity 
remained unchanged. Furthermore, the recommendation highlights additional 
health benefits from muscle-strengthening activities at least two times a week. 
Unlike the previous recommendation, any duration of episodes can be included in 
the accumulated total volume of physical activity (53). 
4.4.3 Smoking 
Over 7 million people die each year because of smoking. Direct smoking causes 
more than 6 million of these deaths, and about 890,000 deaths are caused by the 
exposure to second-hand smoke among non-smokers (54). Smoking prevalence 
varies considerably from one country to another. In Europe, within the population 
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aged 15 years and over, the lowest prevalence of daily smokers was reported in 
Sweden at 11.9%, while the highest prevalence of daily smokers was reported in 
Greece and Turkey at 27.3% in 2014 (55). In Finland, the prevalence of daily 
smoking among men and women in the age group of 20 to 64 years was 15% and 
13%, respectively, in 2018, and the trend is declining (56).  
Even in the 1930s, the hazardous effect of tobacco smoking on life expectancy was 
demonstrated by Raymond Pearl (57). A prospective study of British male doctors 
showed that excess deaths attributable to cigarette smoking were mainly caused by 
ischaemic heart disease, lung cancer, chronic obstructive lung disease and 
atherosclerotic vascular disease (58). Results of 50 years of follow-up of the same 
cohort revealed that smokers lived on average about 10 years less than non-
smokers. However, smoking cessation at ages 60, 50, 40 or 30 extends life 
expectancy by about three, six, nine and 10 years, respectively (59).  
In 2000, in the industrialised world, the leading cause of deaths attributable to 
smoking was CVD (0.75 million male deaths and 0.27 million female deaths), 
accounting for 42.1% of all smoking-attributable deaths (60). Besides active 
cigarette smoking, exposure to environmental tobacco smoke and the use of snuff 
increased the risk for CVD. A meta-analysis of 19 epidemiological studies 
demonstrated that people who have never smoked had 30% greater risk for 
ischaemic heart disease (IHD) at age 65 if they have lived with a smoker. For those 
smoking 20 cigarettes a day, the corresponding risk was 78% (61). The relative risk 
for heart disease of those who have never smoked due to exposure to 
environmental tobacco smoke at work was assessed in a meta-analysis of eight 
prospective studies (62). According to the results, the exposure to environmental 
tobacco smoke in the workplace increased the risk for IHD by 21% compared to 
those who have never smoked without workplace exposure. In an analysis with a 
follow-up of 12 years, the relative risk of death from CVD was 1.4 among snuff 
users, 1.8 among moderate smokers and 1.9 among heavy smokers, respectively, 
compared to non-smokers (63). The habitual use of e-cigarettes has two 
consequences associated with increased CVD risk: a sympathetic dominance in 
cardiac autonomic balance and increased oxidative stress (64,65). 
4.4.4 Alcohol 
Morbidity as well as individual and societal suffering are well-known 
consequences of abundant alcohol use. According to a WHO report, over 3 million 
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deaths can be attributed to the excessive use of alcohol, representing 5.3% of all 
deaths in 2016 globally. Alcohol-attributable deaths are more marked in relatively 
young age groups; in the age group 20–39, such deaths represent 13.5% of total 
deaths (66). In Finland, alcohol-related diseases and accidental alcohol poisoning 
caused 13.7% of all deaths in the working-age population in 2015 (67). Though 
deaths from alcohol-related causes have decreased from 2008 onwards, the number 
of deaths from alcohol-related causes was still greater in 2015 than from any 
neoplasm or IHD (66). Observational studies have shown a dose-dependent 
relationship between alcohol consumption and cardiovascular mortality, giving the 
dependency graph a J-shaped curve. Compared to abstinence or heavy drinking, the 
protective effect concerning CVDs and mortality is achieved with moderate alcohol 
consumption. In a cohort study of more than 67,000 men and women, 15 years of 
follow-up showed that men with an alcohol intake of 15–20 g/day had a hazard 
ratio of 0.75 for cardiovascular deaths and women with an alcohol intake of 10–15 
g/day had a hazard ratio of 0.69 for cardiovascular deaths compared to abstainers. 
Alcohol intake lower or higher than those indicated had higher hazard ratios for 
cardiovascular deaths (68). A meta-analysis of a total of 116,702 subjects depicted 
no threshold between alcohol consumption and the risk for 14 diseases (neoplasm 
and non-neoplasm diseases). A dose-dependent J-shaped relationship was 
discovered only for CHD with a minimum relative risk of 0.80 when alcohol 
consumption was 20 g/day (69). An even greater risk reduction has been found in 
some studies. According to a case-control study, the risk for the first non-fatal 
myocardial infarction was lowest when alcohol intake was 5 to 9.9 g/day, with the 
odds ratio being 0.44, compared with lifelong abstainers (70). 
The causality between the moderate use of alcohol and lower risk for CVD is 
explained by an ethanol-induced increase in insulin sensitivity (71), increase in high-
density cholesterol (72,73) and positive changes in haemostatic factors (72). However, 
the cardio-protective effect is rapidly lost through negative metabolic consequences 
when the amount of alcohol used increases (74). Because it is not predictable for 
whom drinking will become problematic, the beginning of alcohol consumption 
should not be recommended to anyone in a preventive sense (75,76). Until problem 
drinkers can be identified and the balance of beneficial and harmful effects can be 
considered, physicians should apply more innocuous interventions to prevent CHD 
(77,78). Furthermore, the results of recent studies challenge the health benefits of the 
moderate alcohol consumption advanced by previous work. Based on the results of 
a 31-year follow-up, Martin-Diener et al. (79) introduced a chart for the survival 
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probability over the next 10 years of subjects aged 65 and 75 years depending on 
four behavioural risk factors: smoking, fruit intake, leisure-time physical activity 
and alcohol consumption. The chart illustrates that moderate alcohol consumption 
did not improve survival probabilities for any behavioural risk factor combination 
compared to abstainers. The high use of alcohol was associated with a lower 10-
year survival probability compared with abstainers and moderate drinkers. A 
Mendelian randomisation meta-analysis of 56 epidemiological studies including 
260,000 individuals calls into question the beneficial effect of light-to-moderate 
alcohol consumption, suggesting that reductions of alcohol consumption at all 
levels may be beneficial for cardiovascular health (80). 
4.5 Metabolic risk factors 
The main metabolic risk factors contributing to CVD include BP, elevated 
cholesterol, diabetes and obesity. Each alone at non-optimal levels increases the 
CVD risk; the effect is additive, as these factors form a cluster. 
4.5.1 Blood pressure 
High BP is a major risk factor for CHD (81). In 2015, globally, 4.9 million (54.5%) 
of all CHD deaths and 90.1 million (55.1%) of all disability-adjusted life years 
(DALYs) were attributable to an SBP ≥ 110–115 mmHg. With an SBP ≥ 140 
mmHg, the corresponding numbers were 3.6 million (40.1%) for CHD deaths and 
61.7 million (37.6%) for DALYs, respectively (82).  
A study with a median follow-up of 5.2 years in a cohort of 1.25 million people 
indicated that the lowest risk for CVD was among those with an SBP between 90 
and 114 mmHg and DBP between 60 and 74 mmHg. In addition, those with a BP ≥ 
140/90 mmHg and those receiving BP-lowering medication had a lifetime risk of 
CVD at 30 years of 63.3% compared with a lifetime risk of 46.1% among those 
with a normal BP. Furthermore, among those with a normal BP, CVD was 
diagnosed five years later (83).  
The overall burden of hypertension is declining. Worldwide data showed that, in 
the adult population, 26.6% of men and 26.1% of women had hypertension in 2000 
(84), while the corresponding figures were 24.1% in men and 20.1% in women in 
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2015, respectively. In Finland, in a random population-based sample, 40.7% of 
men and 22.4% of women had hypertension in 2012 (85). It is recognised that the 
risk of BP-related CVD increases well below the traditional threshold (140/90 mm 
Hg) for drug treatment.  
At the population level, the optimal prevention of BP-related CVD is achieved 
through lifestyle changes. A meta-analysis of prospective cohort studies, with a 
median follow-up of 9.5 years and including more than 136,000 persons initially 
free from hypertension, demonstrates that high and moderate levels of leisure-time 
PA were associated with a decreased risk of hypertension. Those with high levels 
of PA had a 19% reduction in the risk of hypertension, and those with a moderate 
level of PA had a 11% reduction in the risk of hypertension compared to those with 
low levels of PA (86). A meta-analysis of 54 randomised controlled trials suggests 
that aerobic exercise was associated with a significant reduction in mean systolic 
and diastolic BP. The BP reduction was statistically significant in both 
hypertensive and normotensive participants (87). Typically, a single dietary factor 
has only a modest effect on BP. However, the combined effect of multiple dietary 
factors can be substantial. The most effective diet for controlling BP is the DASH 
diet, a diet rich in fruits, vegetables and low-fat dairy products with a reduced 
content of saturated and total fat. In a study comparing the effect of a typical 
American diet (control), a diet rich in fruit and vegetables and the DASH diet on 
BP, the DASH diet reduced SBP by 5.5 mmHg and DBP by 3.0 mmHg compared 
to a control diet. The corresponding reduction with the diet rich in fruit and 
vegetables was 2.8 mmHg in SBP and 1.1 mmHg in DBP, respectively (88). Another 
study compared the effect of a typical American diet (control) with the DASH diet, 
both diets combined with three levels of sodium intake: high = 3.3 g/day, 
intermediate = 2.5 g/day and low = 1.5 g/day. The reduction of salt consumption 
had a markedly greater effect on BP in the control diet than in the DASH diet. 
Differences in SBP between diets were statistically significant in all sodium 
categories, but in DBP, a statistical significance was not achieved in the low 
sodium category. The maximum difference of -8.9 mmHg in SBP was seen 
between diets in comparing the control diet with the high sodium category to the 
DASH diet with the low sodium category corresponding figure in DBP was -4.5 
mmHg. The variations in BP between groups or between dietary sodium categories 
are shown in Figure 1 (89). 
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In Finland, the intake of sodium among men aged 25–64 years was 3.5 g/day and 
among women 2.6 g/day in 2012. National recommendations are ≤2.8 g/day and 
≤2.4 g/day, respectively (90). 
 
Figure 1. The effect of systolic blood pressure (Panel A) and diastolic blood 
pressure (Panel B) of reduced sodium intake and the DASH diet (Reproduced with 
permission from reference (89). Copyright Massachusetts Medical Society). 
Asterisks (P<0.05), daggers (P<0.01) and double daggers (P<0.001) indicate 
significant distinctions in BP between groups or between dietary sodium 
categories.  
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4.5.2 Overweight and obesity 
BMI is a commonly used measure to indicate an association between weight and 
the risk of diseases. BMI is a person’s weight in kilograms divided by the square of 
height in metres (kg/m2). A Belgian scientist, Adolphe Quételet, initially proposed 
BMI in the middle of the 1800s, and it was initially called the Quételet index.  
 
Table 1. Adult BMI categories according to the WHO (91) 
Underweight  BMI < 18.5 kg/m2 
Normal weight BMI 18.5 kg/m2 to 24.9 kg/m2  
Overweight BMI 25.0 kg/m2 to 29.9 kg/m2  
Obesity class I BMI 30.0 kg/m2 to 34.9 kg/m2  
Obesity class II BMI 35.0 kg/m2 to 39.9 kg/m2 
Obesity class III BMI ≥ 40 kg/m2  
 
In 2015, globally, a total of 107.7 million (5%) children and 603.7 million (12%) 
adults were obese. Among adults, a BMI of 25kg/m2 or more contributed to 4 
million deaths, representing (7.1%) of all deaths globally. Of all deaths associated 
with a BMI of above 25kg/m2, CVD was the leading cause of death. Moreover, 
23.9% of all deaths among overweight persons and 41% of all deaths among obese 
persons were due to CVD (92). Likewise, the prevalence of obesity is rising in 
Europe and has tripled since the 1980s (93). 
In 2012, in a population survey of 8,600 Finns aged 25 to 74 years, the prevalence 
of normal weight in men was 29.9%, overweight 49.1% and obesity 23.4%. In 
women, the figures for normal weight were 36.8%, 38.6%, and 23.8%, respectively 
(94). 
Data from a meta-analysis of 239 prospective studies, including over 10 million 
participants from Asia, Australia, New Zealand, Europe and North America, 
showed that all-cause mortality was lowest at a BMI between 20 kg/m2 and 25 
kg/m2. All-cause mortality increased significantly below that range and throughout 
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all ranges of both overweight and obesity. Another analysis excluded the first five 
years of follow-up and was restricted to those who never smoked without pre-
existing chronic disease, counting almost 4 million participants having BMIs above 
25 kg/m2. In this work, all-cause mortality and mortality involving CHD, stroke, 
respiratory disease and cancer increased progressively with increasing BMI (95). 
Contrary to the study above, findings from a review of 97 studies with 2.9 million 
participants suggested that, in relation to normal weight, obesity class 1 with a BMI 
of 30 kg/m2 to 34.9 kg/m2 was not associated with excess all-cause mortality. 
Overweight with a BMI of 25 kg/m2 to 29.9 kg/m2 was associated with lower all-
cause mortality (96). Notably, this study drew criticism for methodological biases 
like reverse causation and confounding by smoking (97,98). 
Increasing body weight is related to known CVD risk factors including 
hypertension, dyslipidaemia and insulin resistance.  
A study of 243,798 subjects (57% men) with a mean follow-up of 14.1 years 
indicated that the prevalence of hypertension, diabetes and hypercholesterolaemia 
raised with increasing BMI. Among overweight and obese individuals without risk 
factors, the risk for CVD mortality was not significantly higher compared with 
normal-weight individuals without risk factors. The association of overweight with 
hypercholesterolaemia increased the risk for the CVD mortality hazard ratio (HR) 
by 1.45 (95% CI 1.13 to 1.86) in men. A similar increase in the risk was not 
observed in women. A greater increase in the risk of CVD death was seen when 
overweight was associated with hypertension – that is HR 2.05 (1.71 to 2.46) in 
men and 2.15 (1.48 to 3.11) in women. The risk of CVD deaths increased 
considerably in overweight subjects with both hypertension and 
hypercholesterolaemia or both hypertension and diabetes, with an HR: 2.65 (95% 
CI 2.20 to 3.19) and 3.01 (95% CI 2.29 to 3.95) in men, as well as 2.57 (95% CI 
1.80 to 3.68) and 4.50 (95% CI 2.67 to 7.58) in women, respectively. A more 
significant increase in risk was observed in men, but not in women, when 
overweight was associated with all three risk factors: hypertension, diabetes and 
hypercholesterolaemia, with an HR: 3.67 (95% CI 2.78 to 4.85) in men, as well as 
2.87 (95% CI 1.60 to 5.13) in women, respectively (99).  
Individuals differ in their metabolic responses to adiposity. Those with a diagnosis 
of overweight and obesity, based on BMI, but who lack most of the metabolic 
abnormalities have been called metabolically healthy overweight (MHOW) or 
metabolically healthy obese (MHO).  
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In a study of 22,203 men and women (45.2% men) with an average follow-up of 
seven years, 24% of the participants were defined as obese. Among them, 22% 
were categorised as MHO. Subjects were defined as metabolically healthy if they 
had a maximum of one metabolic abnormality: WC > 102 cm in men and > 88 cm 
in women; clinical BP > 130/85 mmHg, hypertension diagnosis, or use of 
antihypertensive medication; HDL cholesterol (< 1.03 mmol/l in men and < 1.30 
mmol/l in women); physician-diagnosed diabetes; or low-grade inflammation (CRP 
≥ 3 mg/l). MHO was not associated with an increased risk of CVD compared with 
the metabolically healthy non-obese; the hazard ratio (HR) was 1.26 (95% CI 0.74 
to 2.13). Both non-obese and obese participants with at least two metabolic 
abnormalities were at an increased risk: HR 1.59 (95% CI 1.30 to 1.94) and 1.64 
(95% CI 1.17 to 2.30), respectively (100). 
Data from a meta-analysis of 14 studies with a total of 299,059 participants showed 
that MHOW and MHO individuals were at an increased risk of CVD events with a 
relative risk (RR) of 1.26 (95% CI 1.10 to 1.45) and 1.56 (95% CI 1.40 to 1.92), 
respectively, compared with healthy normal-weight participants. Correspondingly, 
there was an increased risk of CVD mortality with an RR of 1.30 (95% CI 1.07 to 
1.58) in MHOW and 1.37 (95% CI 1.03 to 1.82) in MHO. The subgroup of 
MHOW participants with a follow-up < 15 years was not at an increased risk for 
CVD, with an RR of 1.05 (95% CI 0.94 to 1.18), whereas the subgroup with a 
follow-up >15 years showed increased risk with an RR of 1.47 (95% CI 1.37 to 
1.58). The MHO participants were at an increased risk of CVD in both subgroups 
(follow-up < 15 years and > 15 years), with an RR of 1.40 (95% CI 1.20 to 1.62) 
and 2 (95% CI 1.79 to 2.24), respectively (101).  
A longitudinal study with a median follow-up of 30 years indicated that, regardless 
of BMI categories (normal weight, overweight and obese), subjects with MetS had 
a higher risk of both total and cardiovascular deaths as well as a greater risk for 
major CVD events than subjects without MetS in the same BMI category. In 
addition, those in the categories of overweight and obesity without MetS had a 
higher risk for major cardiovascular events and total deaths, compared to normal-
weight men without metabolic derangements. The event rate was highest in obese 
subjects with MetS, HR for total deaths, cardiovascular deaths and major CVD 
events: 2.43 (95% CI1.81–3.27), 3.20 (95% CI 2.12–4.82) and 2.55 (95% CI 1.82–
3.58), respectively (102). 
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Although BMI provides a practical measure of obesity, it is not as good as waist 
circumference (WC) to assess metabolically active intra-abdominal fat. WC is easy 
to measure in a clinical setting, and it is strongly correlated to abdominal fat mass, 
subcutaneous fat and intra-abdominal fat, as measured by computed tomography 
(CT) (103).  
In a study of 1,106 participants with a mean follow-up of 6.1 years, CT determined 
the adipose tissue volume of the participants. The results showed that an additional 
500 cm3 increase in  fat volume was associated with an  incident hypertension, the 
odds ratio (OR): 1.21 for subcutaneous adipose tissue (SAT); OR: 1.30 for visceral 
adipose tissue (VAT),  hypercholesterolaemia OR:1.10 for SAT; OR: 1.37  for 
VAT, hypertriglyceridemia OR:1.15  for SAT; OR: 1.56 for VAT, and metabolic 
syndrome OR:1.43  for SAT; OR:1.82 for VAT, respectively (104). 
BMI and WC complement each other in the assessment of adiposity-associated 
cardiometabolic risk. Results from the large international cross-sectional study 
IDEA show that, in all BMI categories (normal weight, overweight and obese), a 1-
SD increase in WC was associated with a significantly higher risk of CVD and type 
2 diabetes. Among those men with a normal weight, the CVD risk increased by 
10%, among the overweight by 19% and among the obese by 23%, among the 
women the CVD risk increased by 15%, 12%, and 24%, respectively. Among those 
men with a normal weight, the risk of type 2 diabetes increased by 27%, among the 
overweight by 23% and among the obese by 34%, among the women the risk of 
type 2 diabetes increased by 43%, 32% and 43%, respectively (105). 
Data from the Health Professionals Follow-Up Study of 27,270 men demonstrates 
the combined effect of overall and abdominal obesity on the risk of type 2 diabetes. 
By taking as a reference group those with a BMI < 25 kg/m2 and WC < 90 cm at 
baseline, in each BMI category (<25 kg/m2, 25 kg/m2 to 29 kg/m2 and ≥30 kg/m2), 
an increased WC (<90 cm, 90 cm to 99 cm and ≥100 cm) predicted a greater risk of 
type 2 diabetes during the 13-year follow-up (106). 
4.5.3 Dyslipidaemia 
Dyslipidaemia is defined as elevations of fasting total cholesterol (TC) 
concentration which may or may not be associated with elevated triglyceride (TG) 
concentration. As lipids are not water soluble, they are transported in plasma in 
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particles known as lipoproteins (107) of which the two most relevant for everyday 
practice are low-density lipoprotein (LDL) and high-density lipoprotein (HDL). 
Dyslipidaemia can occur due to hereditary factors, but more commonly, it is an 
acquired condition. Dietary fatty acids and cholesterol affect serum TC and LDL-
cholesterol as follows: saturated fatty acids and cholesterol increase, 
polyunsaturated fatty acids decrease, and monounsaturated fatty acids have no 
independent effect on serum total cholesterol. The changes in LDL-cholesterol 
were parallel to those in serum total cholesterol, but changes in HDL-cholesterol 
remained uncertain (108). 
Elevated levels of blood lipids are well-documented risk factors for CVD. Findings 
from a 10-year follow-up study of middle-aged participants free from CHD at 
baseline showed that fasting LDL-C, HDL-C and TG are independent predictors of 
CHD. A 1-SD (1.05 mmol/l) increase of TC was associated with a 34% and 32% 
higher risk of CHD in men and in women, respectively. Correspondingly, a 1-SD 
(1mmol/l) increase of LDL-C was associated with a 42% and a 37% higher risk of 
CHD in men and women, respectively (109).  
A study including 5,794 subjects (53.5% women) with an average follow-up of 15 
years showed that the RR of CHD with LDL-cholesterol levels between 130 mg/ml 
and 159 mg/ml (3.36 mmol/l to 4.11mmol/l) was 1.50 (95% CI 1.05 to 2.15) and 
with LDL-cholesterol levels ≥160 mg/ml (4.13 mmol/l) RR was 2.04 (95% CI 1.44 
to 2.90), respectively, compared to an LDL level < 130 mg/ml (3.36 mmol/l). Non-
HDL-cholesterol (total cholesterol minus HDL-cholesterol) showed an even 
stronger association with the incidence of CHD than LDL-cholesterol (110). 
Combined low HDL-cholesterol and high triglyceride levels are also associated 
with an elevated risk for CHD and stroke. A prospective study of 3,216 participants 
without CVD at baseline (40% men, 41% with diabetes) with a median follow-up 
time of 17.7 years showed that participants with combined high TG and low HDL-
cholesterol levels had a 32% and a 46% greater hazard for CHD and for ischaemic 
stroke, respectively, than participants with normal TG and HDL-cholesterol levels. 
When the hazard ratio was assessed among those without diabetes, combined high 
TG and low HDL-cholesterol was not associated with a greater hazard for CHD or 
ischaemic stroke than combined normal TG and normal HDL-cholesterol. 
However, among the diabetics, combined high TG and low HDL-cholesterol was 
associated with a 54% and a 113% greater hazard for CHD and ischaemic stroke, 
respectively, compared to combined normal TG and HDL-cholesterol (111).  
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A meta-analysis of 61 prospective observational studies with almost 900,000 
participants with a mean follow-up of 13 years showed that a 1 mmol/l lower total 
cholesterol was associated with a 56%, 34% and 17% lower ischaemic heart 
disease (IHD) mortality in both sexes at ages 40–49, 50–69 and 70–89 years, 
respectively. HDL-cholesterol-related variables indicated that a 0.33 mmol/l higher 
HDL-cholesterol, a 1 mmol/l lower non-HDL-cholesterol and a 1.33 mmol/l lower 
total cholesterol/HDL-cholesterol were associated with a reduction in IHD 
mortality by one-third (112).  
The effect of increased polyunsaturated fatty acid (PUFA) intake as a replacement 
for saturated fatty acid (SFA) on CHD endpoints was analysed using the pooled 
results of eight randomised controlled trials, including a total of 13,614 participants 
(21.2% with established CHD) with a median follow-up time of 4.25 years. In the 
intervention groups, the average PUFA consumption was 14.9% of total energy 
intake; in the control groups, average PUFA consumption was 5% of total energy 
intake. The results showed that, compared to the control group, the mean decrease 
in total cholesterol levels in the intervention group was 0.76 mmol/l, corresponding 
to a risk reduction of 24% for a 1 mmol/l reduction in TC. The overall CHD risk 
reduction was 19%, corresponding to a 10% less CHD risk for each 5% energy 
increment from PUFA. In four studies lasting less than 4.25 years and another four 
studies of at least 4.25 years, the pooled CHD risk reduction was 9% and 27%, 
respectively. In four studies evaluating primary prevention populations and another 
four studies evaluating secondary prevention populations, the pooled CHD risk 
reduction was 24% and 16%, respectively (113). 
In a study of randomly assigned 174,149 participants (27% women) statin therapy 
reduced major vascular events by 24% per each 1 mmol/l reduction in LDL-
cholesterol. The reduction was significant in both women and men. In a subgroup 
with no known history of vascular disease, the reduction was 25% and among those 
with a history of vascular disease 21%, respectively. Overall vascular mortality was 
reduced by 12% and deaths from unknown cause by 13% per each 1mmol/l LDL-
cholesterol reduction. Deaths from non-vascular causes were reduced by 4% (114). 
4.5.4 Impaired glucose homeostasis 
Glucose homeostasis is the balance between insulin and glucagon secretion to 
maintain blood glucose. The consequences of balance disturbance are impaired 
fasting glucose, impaired glucose tolerance and type 2 diabetes.  
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It is estimated that, in 2015, among the global adult population aged 20–79 years, 
the number of people with diabetes was 415 million, a figure projected to rise to 
642 million by 2040 (115). In 2016, there were about 300,000 people with type 2 
diabetes in Finland and an additional estimated 150,000 undiagnosed cases (116). 
Diabetes is associated with an increased risk of CHD. Analyses of data from 
prospective cohort studies with a duration of follow-up from four to 36 years 
revealed that people with diabetes had a rate of fatal CHD events of 5.4% and those 
without diabetes of 1.6%, respectively. Rates vary between sexes. The fatal event 
rate in women (with and without diabetes) was 7.7% and 1.2%, respectively. The 
corresponding event rates in men were 4.5% and 2%; see Figure 2. 
 
Figure 2. Difference in type 2 diabetes and fatal coronary heart disease events between 
men and women 
Regarding RR, in women, the risk for a fatal CHD event was 3.5 (95% CI 2.70 to 
4.53), and among men, 2.06 (95% CI 1.81 to 2.34) (117). A similar trend was 
reported in a study using data from the Emerging Risk Factors Collaboration 
databank. Analyses included data from people with and without diabetes. By 
comparing people with diabetes to people without diabetes, the hazard ratios for 
CHD were 1.89 (95% CI 1.73 to 2.06) in men and 2.59 (95% CI 2.29 to 2.93) in 
women, respectively. The corresponding hazard ratios for ischaemic stroke were 
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2.16 (95% CI 1.84 to 2.52) in men and 2.83 (95% CI 2.35 to 3.40) in women, 
respectively (118). 
During a seven-year follow-up, there were no significant distinctions in the hazard 
ratios for fatal CHD between diabetic subjects without prior myocardial infarction 
and non-diabetic subjects with prior myocardial infarction. The hazard ratio was 
1.2 (95% CI 0.6 to 2.4) when adjusted for age, sex, total cholesterol, hypertension 
and smoking. The result suggests an equal risk of myocardial infarction in the two 
groups 119. Like the previous work, a Danish register-based study demonstrated that 
diabetic individuals have a cardiovascular risk comparable to non-diabetics with 
prior myocardial infarction 120. 
There is also evidence of an association between pre-diabetes and an increased risk 
for CVD. Based on the results of a systematic review that included 175,152 people, 
the authors suggest that IFG and IGT are linked with a modest increase in the risk 
for CVD (121). Meta-analyses of 20 studies with a mean follow-up of 12.4 years 
including 95,783 non-diabetic people indicated that fasting and postprandial 
hyperglycaemia are associated with CVD. A fasting plasma glucose level of 6.1 
mmol/l, the threshold value for IFG and a 2-h glucose level of 7.8 mmol/l, the 
threshold value for IGT were associated with a 30% and 58% increase in risk for a 
cardiovascular event, respectively, compared to a fasting glucose level of 4.2 
mmol/l (122). 
The results of a study comparing intensive lifestyle intervention and lifestyle 
advice only among persons with IGT disclose that, although the intensive lifestyle 
intervention reduced the incidence of type 2 diabetes, it did not lessen 
cardiovascular morbidity during a 10-year follow-up (123). 
Among old-line diabetes medications, metformin has been considered, over 
decades, to possess the best properties to reduce diabetes-related endpoints. In a 
sub-study of the United Kingdom Prospective Diabetes Study, glucose control with 
metformin proved to be more effective in reducing the risk of diabetes-related 
complications than sulfonylurea or insulin among overweight diabetics. Compared 
to the dietary treatment group, the metformin group had a 32% lower risk for 
diabetes-related endpoints, while the corresponding risk reduction in the 
sulfonylurea or insulin group was 7%. For all-cause mortality, the risk reduction 
was 36% in the metformin group and 8% in the sulfonylurea or insulin group, 
respectively. The risk reduction of myocardial infarction was 39% in the metformin 
group and 21% in the sulfonylurea or insulin group, respectively (124).  
34 
 
Novel blood-glucose-lowering medications, such as sodium-glucose cotransporter 
2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists, have been 
shown to reduce the risk of major adverse cardiac events (125). According to a meta-
analysis with 351,476 diabetics, SGLT-2 inhibitors significantly reduced all-cause 
mortality, cardiovascular mortality and non-fatal myocardial infarction with hazard 
ratios of 0.67 (95% CI, 0.54 to 0.84), 0.77 (95% CI, 0.60–0.98) and 0.86 (95% CI, 
0.76–0.98), respectively (126). In a study using network meta-analysis, the authors 
reported the clinical efficacy of SGLT-2 inhibitors, GLP-1 agonists and dipeptidyl 
peptidase 4 (DPP-4) inhibitors in the treatment of type 2 diabetes. Compared to the 
controls, the hazard ratio for cardiovascular mortality was 0.79 (95% credible 
intervals {CrI}, 0.69 to 0.91) for SGLT-2 inhibitors, 0.85(95% CrI, 0.77 to 0.94) 
for GLP-1 agonists and 1.0 (95% CrI, 0.91 to 1.11) for DPP-4 inhibitors. The 
corresponding absolute risk difference (RD) was -0.8 (95% CrI, -1.1 to -0.3) for 
SGLT-2 inhibitors, -0.5(95% CrI, -0.8 to -0.1) for GLP-1 agonists and 0.0 (95% 
CrI, -0.3 to 0.4) for DPP-4 inhibitors, respectively. The hazard ratios for all-cause 
mortality were comparable to the hazard ratios for cardiovascular mortality with all 
three medications (127). Moreover, SGLT-2 inhibitors have shown to improve 
cardiac function, providing additional benefits to diabetics experiencing heart 
failure (128). 
4.6 Overall cardiovascular risk  
Historically, cardiovascular (CV) risk has been assessed based on a single risk 
factor. The understanding that several interacting risk factors determine 
atherosclerotic CVD led to the introduction of the concept of ‘total CV risk’.  
In 1991, based on the Framingham study cohort of 5,573 subjects (53.5% women), 
a risk function was published to assess five- and 10-year risk for CHD. The 
following risk factors were considered in the risk function: age, sex, systolic and 
diastolic BP, total cholesterol, HDL-cholesterol, diabetes, smoking status and left 
ventricular hypertrophy based on ECG findings (129). Subsequently, several 
modified versions of the Framingham risk function have been published, including 
a version where left ventricular hypertrophy is omitted and LDL-cholesterol is 
optionally added for use instead of total cholesterol (130). In 1994, the first 
‘European recommendations on the prevention of coronary heart disease in clinical 
practice’ were introduced. The recommendations were comprised of a coronary 
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risk chart to assess the absolute 10-year risk for CHD. The risk function and the 
chart based on the risk function were derived from the above-mentioned 
Framingham Study, but fewer risk factors were included, that is age, sex, SBP, 
total cholesterol and smoking (131). A year before the European recommendations, 
the National Advisory Committee on Core Health and Disability Support Services, 
New Zealand, published recommendations according to which the treatment of 
raised BP should be based on the absolute risk of CVD rather than on BP alone 
(132). 
The European Recommendations on the Prevention of Coronary Heart Disease in 
Clinical Practice were updated in 1998. The updated recommendations considered 
the accumulated new scientific evidence of lifestyle guidance and medication to 
achieve risk factor goals. However, the CHD risk-estimating chart remained 
unchanged (133). The Systematic Coronary Risk Evaluation (SCORE) Project was 
initiated in 1994 as a joint venture between the European Societies of Cardiology 
and Hypertension and the European Atherosclerosis Society. A European scoring 
method was deemed necessary due to shortcomings with the use of risk scoring 
based on the Framingham study from the U.S. The Framingham scoring method 
was based on a rather small population (5,573 people), and it overestimated the risk 
of cardiovascular events in some European populations. Furthermore, the end point 
was morbidity and mortality from CHD, not total cardiovascular mortality as in the 
SCORE project (134). ‘Estimation of Ten-Year Risk of Fatal CVD in Europe: The 
SCORE Project’ was published in 2003. It was based on 12 pooled prospective 
studies from 11 European countries, including 205,178 people (88,080 women and 
117,098 men) representing 2.7 million person years of follow-up and 7,934 
documented cardiovascular deaths. The SCORE model, based on this data, 
estimates the absolute 10-year risk of a first fatal cardiovascular event, including all 
International Classification of Disease codes that can be considered to be 
atherosclerotic. The built-up risk equation was a function of age, gender, SBP, total 
cholesterol or total cholesterol and HDL-cholesterol ratio, and smoking status. Two 
SCORE risk charts were compiled, one for high-risk and one for low-risk regions 
of Europe. Both regional charts had parallel charts, one with total cholesterol and 
the other with total and HDL-cholesterol ratio as lipid variables. The SCORE 
model is intended for risk stratification in the primary prevention of CVD (135, 136). 
The latest version of ‘European Guidelines on CVD Prevention in Clinical 
Practice’ was published in 2016 (3). The European Guidelines categorise CVD risk 
on four levels: very high-risk, a calculated SCORE ≥ 10%; high-risk, a calculated 
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SCORE ≥5% but <10%; moderate risk, a calculated SCORE ≥1% but<5%; and 
low-risk, a calculated SCORE <1%. The recommendation follows the principle that 
the higher the risk, the more intense the treatment approach should be. To guide 
preventive measures, the latest guidelines equate the following situations with a 
very high risk: documented CVD, DM with target organ damage such as 
proteinuria or with a major risk factor, severe chronic kidney disease (CKD) – that 
is GFR <30 ml/min/1.73 m2, with a high risk: DM (with the exception of young 
people with type 1 DM without major risk factors) and those with moderate CKD - 
that is a GFR 30–59 ml/min/1.73 m2 (3).  
There are substantial differences between European countries regarding CVD 
deaths (137). Relatively high age-standardised death rates can be identified in 
Eastern and Central Europe, while the rates are lower in Northern, Western and 
Southern Europe (138). 
The SCORE model has the advantage that it can be recalibrated at the national 
level. Recalibration requires recent and precise estimates of mortality and risk 
factor statistics. Recalibrated country-specific versions of the SCORE model exist 
for 17 European countries. Based on SCORE risk charts, a web-based calculator 
called HeartScore was produced. HeartScore includes versions of high- and low-
risk countries, total cholesterol and the total cholesterol/HDL-cholesterol ratio (139). 
Since 2008, it has been possible to estimate the 10-year risk for CHD, stroke and 
their combination by Finland’s calculator, FINRISK (140). The model is based on a 
10-year follow-up of a random population sample of 19,447 citizens (52% women) 
from three cohorts in 1982, 1987 and 1992 of the FINRISK survey. The model 
estimates a 10-year risk for CHD, stroke and their combination. The risk is 
predicted by sex, age, smoking, SBP, total cholesterol, HDL-cholesterol, diabetes 
and family history of CVD (141).  
Other models have been developed to stratify the asymptomatic population on the 
basis of total CV risk into the subgroups of low, moderate, high and very high risk. 
Most models are based on major CV risk factors, that is age, gender, smoking, BP 
and lipids. A few other risk factors have been included in commonly used models 
(Table 2). Over the last decade, researchers have attempted to discern whether 
adding novel biomarkers to existing models will improve the total CV risk 
estimation.  
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It can be concluded from the literature that, in estimating the total CV risk of an 
asymptomatic person, traditional cardiovascular risk factors explain most of an 
individual’s risk. Adding novel biomarkers from the fields of inflammation, 
coagulation or subclinical vascular damages has only modest and inconsistent 
effects on existing models (142). Therefore, their usage should be limited to subjects 
with the therapeutic dilemma of an intermediate total CV risk (143, 144). 
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4.7 Risk screening and health counselling 
‘There should be no screening without adequate resources for advice and long-term 
care’, on page 70 of The Strategy of Preventive Medicine, by Geoffrey Rose (1992) 
 
A one-year follow-up study included 100 men and women (64% women) with a 
mean age of 56 (±10) years. The inclusion criterion of the study was at least three 
of the following cardiovascular risk factors: physical inactivity, unhealthy eating 
habits, smoking, risky consumption of alcohol, high prolonged stress, overweight, 
abdominal obesity, dyslipidaemia, high BP, insulin resistance, diabetes or previous 
CVD. The study’s process included a health check-up, risk assessments and 
lifestyle counselling at baseline, at six months and at one year. Between the 
baseline and six-month visits, there were five group sessions. During the one-year 
study period, the change in proportions of high SBP was from 49% to 30% and in 
DBP from 38% to 19%, respectively. Systolic BP decreased from 135 mmHg at 
baseline to 130 mmHg at the one-year visit, and mean DBP decreased from 85 
mmHg to 80 mmHg. A decreasing trend of systolic and diastolic BP was found 
among participants with and without BP-lowering medication. WC decreased over 
the study period from 108.4 cm to 105.9 cm. TC concentrations decreased from 5.1 
mmol/l at baseline to 4.9 mmol/l at the six-month visit. No further change was seen 
at the one-year visit. A similar trend was reported in LDL-cholesterol. The overall 
cardiovascular risk according to the Framingham 10-year predicting model 
decreased significantly from the baseline (15.6%) to the one-year follow-up 
(13.3.%) in the total study population. At the baseline, the overall cardiovascular 
risk was 23.5% in men and 10.8% in women, respectively. At the one-year visit, 
the corresponding numbers were 18.4% for men and 8.6% for women. The risk 
reduction over the one-year period was practically the same for men and women – 
21.7% and 20.3%, respectively. The risk reduction was 21% among those with 
CVD and 28% among those without CVD 151. 
A systematic review of 74 trials targeted healthy lifestyle counselling for 
individuals with cardiovascular risk factors, of which 49 trials evaluated combined 
lifestyle counselling (healthy diet and physical activity) interventions, 18 diet-only 
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interventions and 10 physical activity-only interventions. At the 12- to 24-month 
follow-up, combined lifestyle counselling intervention trials reported decreased 
total cholesterol and LDL-cholesterol levels, BP, fasting glucose levels, diabetes 
incidence and weight. Diet-only counselling also reduced total cholesterol and LDL 
cholesterol levels. The authors did not find consistent evidence of benefits for 
cardiovascular risk factors from evaluated physical activity-only trials 152.  
In another study, 168 middle-aged men with at least two cardiovascular risk factors 
who were physically inactive (physical activity < 3 times per week) were divided 
into three groups: lifestyle counselling, lifestyle counselling plus three months of 
weekly group exercise intervention and a control group. At the one-year follow-up 
visit, the total proportion of physically active participants (PA ≥ 3 times per week) 
was 19%. Viewed by group, in the lifestyle counselling-only group, the physically 
active proportion was 16%, in the lifestyle counselling plus exercise intervention 
26% and in the control group 17%, respectively. The results did not show 
meaningful impact on any other cardiovascular risk factors 153. Another study 
including the same population as above reported significant improvements in self-
rated health and self-rated wellbeing across all groups. Moreover, the proportion of 
depressive participants, assessed by the Patient Health Questionaire-2, decreased in 
two intervention groups but not among the controls during the one-year study 
period. The participants with a depressive score ≥3 decreased from 27% to 13% in 
the group receiving lifestyle counselling only, lessened from 34% to 18% in the 
group receiving lifestyle counselling plus exercise intervention and increased from 
26% to 31% in the control group 154. 
The current practice has brought a new approach to cardiovascular risk 
management. In a systematic review and meta-analysis, a total of 57 studies (n = 
19,862) evaluated the impact of Web-based intervention on cardiovascular risk 
factor management to reduce the risk of CVD in older people. In a subgroup 
analysis of eight studies (n = 2,321) targeting overall cardiovascular risk scores, a 
small but significant improvement was detected during the follow-up in risk score 
value – that is a weighted standardised mean difference of -0.10 (95% CI -0.18 to -
0.02; I2=0%) 155. A web-based health risk assessment study with tailored feedback 
regarding individual health promotion evaluated the effects on the lifestyles of 
employees at a Dutch worksite. Their mean age was 45 years. Gender was not 
reported. The mean follow-up time was 15 months. Positive changes were detected 
only in physical activity, as the proportion of those who performed physical 
activity ≥150 min per week increased from 46% at the baseline to 71% at the 
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follow-up. No difference was seen in the proportions meeting the recommendations 
for the daily intake of fruit and vegetables, moderate alcohol consumption and 
smoking cessation 156. 
Several on-line applications are available for health checks and counselling. One is 
the Virtual Health Check and Personal Coaching programme developed by the 
Finnish Medical Association Duodecim. The virtual health check provides users 
with information about risk factors aimed at improving their health. Based on risk 
profile, the programme estimates life expectancy and disease risk. A registered user 
can start an eight- to 12-week coaching programme that provides regular feedback. 
The Virtual Health Check and Personal Coaching application is available at 
https://starscience.duodecim.fi/star_de. 
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5 AIMS OF THE STUDY 
In this series of studies, we investigated the relationship between central obesity 
and cardiovascular risk factors and evaluated the long-term effect of lifestyle 
counselling on cardiovascular risk factors in middle-aged men. 
The aims of the studies were: 
1. To assess the predictive value of a single anthropometric measure, WC, as a 
cardiovascular risk indicator (study I). 
2. To explore the associations between abdominal fat deposits and 
cardiovascular risk factors in abdominally obese middle-aged men (study 
II).  
3. To evaluate the impact of lifestyle counselling based upon personal 
cardiovascular risk estimation during a two-year follow-up considering 
individual socioeconomic status (study III). 
4. To evaluate the long-term influence of risk assessment and lifestyle 
counselling on lifestyle, cardiovascular risk factors and total cardiovascular 
risk considering the continuation of risk communication without a 
preconceived plan (study IV).  
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6 METHODS 
6.1 Subjects 
6.1.1 Study I 
 
Figure 3. Flow chart of Study I 
The Health Centre of the City of Helsinki and the Helsinki Heart District conducted 
a study called the MBO project between 2001 and 2005 (157). The study’s 
population consisted of men aged 40, 45, 50 and 55 living in the north-eastern part 
of Helsinki. The study was intended to develop a method by which to identify 
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cardiometabolic risk factors among middle-aged men, to make them aware of their 
risks and to encourage risk management. At a risk assessment visit in the Helsinki 
Heart District with a public health nurse, men with an elevated risk were given 
lifestyle counselling and were invited to a follow-up visit within six months’ time.  
The present study deals with data from the youngest (men age 40) cohort of the 
MBO project collected at the first visits in 2001. The potential study population 
comprised 715 invitations to men aged 40. Of these men, 234 responded and 
participated in the risk assessment visits. Due to the lack of data from 38 subjects, 
196 subjects were included in the final analyses (Figure 3). 
 
6.1.2 Study II 
This part of the thesis deals with the original study 2 only to the extent that it 
describes the associations between abdominal obesity and CV risk factors.  
Through advertisements in local newspapers, 77 middle-aged men were recruited 
to the study. The participants had to meet the following criteria: no known acute or 
chronic disease based upon history, physical examination or a standard laboratory 
test (diabetes or its absence was confirmed by a 2-h oral glucose tolerance test) and 
an alcohol consumption of ≤ 20 g per day. Participants were allocated into two 
groups with or without metabolic syndrome (Mets), based on the harmonised 
criterion of MetS (158). Thirty-seven participants out of 77 fulfilled the criterion for 
the MetS.  
6.1.3 Studies III and IV 
Since 2006, the City of Helsinki has provided a systematic cardiometabolic risk 
assessment including a lifestyle interview and counselling for all men aged 40 
living in Helsinki. Initially, these activities were launched with the Helsinki Heart 
District, a member of the Finnish Heart Association. The latter was the initiating 
party and was responsible for training the study’s nurses and developing the tools 
used for guidance. Of the 4,274 men originally invited to the risk assessment visit 
in 2006, 1,454 (34%) participated. Out of these, 471 men were found with an 
elevated CV risk assessed with a modified North-Karelia project risk tool (159). All 
men with an elevated CV risk received lifestyle counselling based on their 
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individual risk profile according to current guidelines for preventing CVD, which 
was in line with European guidelines on CVD prevention in clinical practice (133). 
The 60-minute-long session (lifestyle interview and counselling) with a public 
health nurse was supplemented with printed health education materials addressing 
physical activity, smoking cessation and dietary habits. The educational material 
was produced by the Finnish Heart Association and the Finnish Diabetes 
Association. The lifestyle interview included questions about types of fat used for 
bread spreads and for cooking. The alternatives were vegetable margarine, 
vegetable oil and butter. Information about leisure-time physical activities and 
smoking habits was collected by a questionnaire (Appendix 2). All men with an 
elevated risk were advised to be in contact with healthcare providers for CV-risk 
monitoring every one to two years. Future visits depended on the men's own 
motivation, without any preconceived plan. They were to choose their own service 
provider, that is their local healthcare centre for normal day-to-day practice, 
occupational health services or private healthcare services. According to the study 
plan, all participants would be invited to attend follow-up visits after two and five 
years. Those who took part in a two-year visit in 2008 and a five-year visit in 2011 
gave their written informed consent for their participation at that visit. 
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Table 3. Modified cardiovascular risk score of the North Karelia project 
   
Score 
BMI 
kg/m2 
Current 
smoking 
Physical 
activitya 
Systolic 
BP 
mmHg 
Diastolic 
BP 
mmHg 
Cholesterol 
mmol/l 
0 ≤ 24.9 0 ≥ 3x/week ≤ 129 ≤ 79 ≤ 4.9 
0.5 
25–
26.9 Occasionally 1–2x/week 130–139 80–89 5.0–5.4 
1.0 
27–
28.9 1–4/day 
Approx. 
1x/week 140–149 90–94 5.5–5.9 
1.5 
29–
30.9 5–9 Sometimes 150–159 95–99 6.0–6.4 
2.0 ≥ 31 10–14 Never ≥ 160 ≥ 100 6.5–6.9 
2.5 – 15–19 – – – 7.0–7.4 
3.0 – 20–24 – – – 7.5–7.9 
3.5 – 25–29 – – – 8.0–8.4 
4.0 – 30 – – – ≥8.5 
BMI = body mass index, BP = blood pressure and TC = total cholesterol. a 
Continuous physical exercise (duration at least 30 min) causing sweating or 
shortness of breath. According to the criteria used, high-risk persons have a risk 
score of ≥ 4.5 (sum of scores). 
6.2 Measurements and examination  
6.2.1 Studies I, III and IV 
At the screening visit, detailed information on leisure time physical activity 
(LTPA), smoking habits, use of alcohol and family history of CVD and diabetes, 
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among others, was obtained from a self-administered questionnaire (appendices 1 
and 2) which was completed by a nurse at the examination. In addition, dietary 
habits were assessed. Height was measured to the nearest 0.1 cm and weight to the 
nearest 0.1 kg in light indoor clothing without shoes. BMI was calculated as kg/m2. 
WC was measured once in a standing position midway between the lowest rib and 
the iliac crest. Blood pressure was measured with the subject in a sitting position 
using an automated sphygmomanometer (Omron HEM-7051-E, Kyoto, Japan). The 
mean of two successive readings was recorded. All measurements were made in 
accordance with standard techniques. Blood samples were drawn by a trained 
technician after an overnight fast and analysed for lipids and glucose in a certified 
central laboratory. CVD risk was assessed using a modified version of the North-
Karelia project risk chart (Table 3 and Appendix 2) which is based on BMI, 
smoking status, leisure-time physical activity, systolic and diastolic BP and total 
cholesterol concentration (152,160). The risk score can range from zero to 16. Subjects 
with a risk score ≥ 4.5 are considered to have an elevated risk for CVD. The 
Finnish Diabetes Risk Score (FINDRISC) (appendix 1) was used to assess the risk 
for type 2 diabetes (161). 
6.2.2 Study II 
WC was measured once in a standing position midway between the iliac crest and 
the lowest rib margin. BMI was calculated as kg/m2. Blood pressure was measured 
by BPM-200 (Quick Medical, Snoqualmie, Washington) in the sitting position after 
a five-minute rest, and the mean of five measurements was recorded. Blood 
samples were drawn after overnight fasting. Total serum cholesterol, TG, very low-
density lipoprotein cholesterol (VLDL-1) TG, HDL-C, free fatty acids, 
apolipoprotein A-I, apolipoprotein B and high-sensitivity C-reactive protein (CRP) 
were measured by an autoanalyzer. The concentration of low-density lipoprotein 
cholesterol was calculated using the Friedewald formula (162). Fasting glucose and 
standard two-hour 75 g oral glucose tolerance tests were performed; plasma 
glucose was assessed using the hexokinase method. Insulin concentration was 
determined by a two-site immunoradiometric assay. The insulin-resistance 
homeostasis model assessment (HOMA) index was calculated using the formula: 
(fasting plasma glucose x fasting plasma insulin)/22.5 (163). Smoking status was 
recorded as present, past or non-smoker. 
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Hepatic TG content, distribution and volumes of visceral adipose tissue (VAT) and 
subcutaneous adipose tissue (SAT) were measured with a whole-body magnetic 
resonance (MR) imager. The VAT/SAT ratio was calculated as a metric of 
abdominal fat distribution.  
6.2.3 Study III follow-up 
 
Figure 4. Flow chart of studies III and IV 
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Of the men with an elevated risk (n = 471) at the screening visit in 2006, a total of 
430 were identified from the local healthcare centre register in 2008 and were 
invited to a follow-up visit. Of these, 200 (47%) participated. Information on 
educational attainment was available for 185 (93%) of the men (Figure 4). The 
subjects experienced the same examinations and were interviewed about lifestyles 
in a similar way as at the screening visit. Since the collected data enabled CV-risk 
assessment while applying the Framingham equation for primary healthcare (145), 
this CVD assessment was included in the study. To determine the impact of 
socioeconomic status (SES) on CV-risk factors during the two-year follow-up 
period, we categorised men into three levels according to their educational 
attainment (low ≤ 9 years, middle 10 to 12 years and high ≥ 13 years). 
6.2.4 Study IV follow-up 
In 2011, a total of 389 men who originally had an elevated CV risk were identified 
from the local healthcare centre register and were invited for a re-evaluation visit. 
Of these, 159 (41%) participated (Figure 4). These men underwent the same 
examinations and were interviewed for lifestyles in a similar way as at the 
screening visit. In addition, their CV risk was assessed with the SCORE Chart (3). 
Information was collected about fulfilled contacts with healthcare providers for 
CV-risk monitoring after the baseline screening visit. Contacts with the public 
healthcare centre were checked from the medical records of the participants, but 
information on contacts with occupational healthcare was based on participants’ 
own reports. 
6.3 Statistical methods 
6.3.1 Study I 
Calculations of sensitivity, specificity and predictive values of 11 cut-off points for 
WC (92 cm through 102 cm) were based on a 2 x 2 contingency table, where WC 
was used as the independent variable and the risk status as the dependent variable. 
The former calculation was performed with the Confidence Interval Analysis 
(CIA), for Windows version 2.1.2 software according to Wilson’s method. The 
receiver operating characteristic (ROC) curve was constructed with SPSS statistics 
using WC as the test variable and the risk status as the state variable. 
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6.3.2 Study II  
The distribution of continuous variables was analysed by the Kolmogorov-Smirnov 
test. Data were presented as means with standard deviations for normally 
distributed variables, as medians in the 0.25–0.75 interquartile range for skewed 
variables and as percentages for categorical variables. The Mann-Whitney U test, 
unpaired t test and χ2 test were applied, as appropriate, to assess between-group 
differences. Correlation analyses were adjusted for age and smoking status. 
Univariate regression analyses were performed to detect determinants of hepatic 
TG content, visceral fat and VAT/SAT ratio. Stepwise multivariable linear 
regression analyses were used to evaluate the impact of fat deposits on 
cardiometabolic risk factors as dependent variables  
6.3.3 Studies III and IV  
The data are presented for continuous variables as means with standard deviations 
and categorical variables as percentages. The 95% confidence intervals are given 
for differences of the means. The comparison of continuous variables within one 
group (between baseline and follow-up visits) was performed with paired t-tests. 
The one-way ANOVA was performed to determine distinctions in continuous 
variables between the groups. Within-group changes in continuous variables were 
compared between the groups with the Univariate General Linear model.  
The comparisons of categorical variables within one group (between baseline and 
follow-up visits) were performed with Wilson’s method for paired samples’ 
proportions and their distinctions using Confidence Intervals Analysis (CIA) 
software for Windows. The differences of categorical variables between the groups 
were analysed by Freeman-Halton extension of Fisher’s exact test (164). Within-
group changes in categorical variables were compared between the groups with the 
Binary Logistic Regression model. 
 Unless otherwise stated, the statistical software used was: study I, SPSS 16.0 for 
Windows (SPSS Inc., Chicago IL, USA); study II, SPSS 19.0 for Windows (SPSS, 
Inc., Chicago, Illinois, USA); study III, SPSS 18.0 for Windows (SPSS INC., 
Chicago IL, USA); and study IV, SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, 
USA). 
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6.4 Ethical considerations 
The Helsinki University Central Hospital Ethics Committee approved the protocol 
of all studies, and in all studies, subjects provided their written informed consent. 
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7 RESULTS 
7.1 Study I 
Of the 715 invited men, 234 (32.7%) participated in the risk assessment visits at 
Helsinki heart district. At the beginning of recruitment in 2001, the FINDRISC 
chart was unavailable. Therefore, the assessment of FINDRISC was missing from 
38 men. Sufficient data for analyses were available from 196 men. In 87 
participants, neither of the risk scores (CVD risk score or FINDRISC score) was 
elevated; at least one of the risk scores was raised in 109 men. Among these, 67 
had a CVD risk score ≥ 4.5, and 82 had a FINDRISC ≥ 7. Both risk scores were 
elevated in 40 participants. Table 4 shows the characteristics of the participants 
grouped according to risk status. The variation in individual risk factors is at its 
highest 20% between the low-risk and the elevated risk groups. Notably, those with 
elevated risk have two to three times higher RR for CVD and type 2 diabetes 
compared with low-risk participants. 
 
Table 4. Characteristics of the participants according to risk status 
 CVD risk < 4.5 and FINDRISC < 7 CVD risk ≥ 4.5 FINDRISC ≥ 7 
 n = 87 n = 67 n = 82 
BMI kg/m2  23.9 (2.5) 28.3 (4.0) 28.9 (3.7) 
WC cm            90.0 (6.4) 102.3 (10.5) 104.1 (10.0) 
SBP mmHg 125 (13.1) 139 (16.9) 134 (14.8) 
DBP mmHg 82 (8.1) 93 (9.9) 89 (9.2) 
Total-C mmol/l 4.54 (0.79) 6.00 (0.97) 5.28 (1.07) 
LDL-C mmol/l 2.45 (0.93) 3.95 (0.92) 3.24 (1.06) 
HDL-C mmol/l 1.67 (0.46) 1.29 (0.36) 1.32 (0.40) 
TG mmol/l 1.58 (0.46) 1.69 (0.77) 1.84 (0.88) 
Glucose mmol/l 5.37 (0.74) 5.45 (0.54) 5.38 (0.53) 
FINDRISC 3.1 (2.0) 7.5 (3.6) 9.2 (2.4) 
CVD risk score 2.0 (1.2) 6.8 (1.8) 4.8 (2.7) 
Data are means and (SD). BMI = body max index, WC = waist circumference, SBP 
= systolic blood pressure, DBP = diastolic blood pressure, Total-C = total 
cholesterol, LDL-D = low-density lipoprotein cholesterol, HDL-C = high-density 
lipoprotein cholesterol, TG = triglycerides.  
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Figure 5. The receiver operating characteristic curve. The arrow on the curve 
corresponding waist circumference of ≥ 94 cm with coordinates; sensitivity = 0.844 and 1- 
specificity = 1- 0.782. 
In Figure 5, the area under the curve is 0.858 (95% CI; 0.805 to 0.910). The area 
under the curve decreases when the cut-off of the FINDRISC score is raised from 7 
to 9 and further to 12. The corresponding area under the curve is as follows: 0.773 
(95% CI 0.707 to 0.831) and 0.761 (95% CI 0.690 to 0.831).  
7.2 Study II 
Clinical and biochemical characteristics of the study’s subjects are summarised in 
Table 6 In all of the parameters presented, the difference between the groups was 
statistically significant. All participants without MetS had normal glucose 
tolerance, whereas in the MetS group, four participants had impaired fasting 
glucose, and nine, impaired glucose tolerance. Subjects with a high level of intra-
abdominal fat presented characteristics of MetS, elevated WC, triglycerides, insulin 
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resistance, BP and decreased HDL-cholesterol compared to subjects with a low 
level of intra-abdominal fat. They were also overall older, with higher BMI and 
pronounced smoking habits compared to subjects with lower levels of intra-
abdominal fat. The difference between the groups in the amount of visceral fat was 
considerable, being 3.9 times higher in the MetS group than those without MetS. 
Table 6. Characteristics of the study’s groups 
 MetS present MetS absent P values 
N (men) 37 40  
Age, y 47 (6) 40 (8) < 0.001 
Current smoker, n (%) 13 (35) 5 (12) 0.019 
WC, cm 107.0 (94.0─135.0) 87.0 (71.0─93.5) < 0.001 
BMI, kg/m2 30.9 (24.2─42.5) 23.4 (17.6─29.8) < 0.001 
Systolic BP, mmHg 132 (14) 115 (10) < 0-001 
Diastolic BP, mmHg 88 (9) 74 (6) < 0.001 
Total cholesterol, mmol/l 5.25 (0.74) 4.41 (0.79) < 0.001 
LDL-cholesterol, mmol/l 3.25 (0.71) 2.54 (0.66) < 0.001 
HDL-cholesterol, mmol/l 1.02 (0.26) 1.50 (0.39) < 0.001 
TG, mmol/l 2.20 (0.65─6.26) 0.78 (0.35–1.57) < 0.001 
fP-glucose, mmol/l 5.8 (4.6–6.9) 5.0 (4.4─6.0) < 0.001 
fS-insulin, mU/l 9.3 (3.3─36.9) 2.9 (0.9─7.7) < 0.001 
HOMA index 2.6 (0.8─8.0) 0.6 (0.2─2.0) < 0.001 
High-sensitivity CRP, mg/l 1.8 (0.2─11.8) 0.2 (0.0─5.8) < 0.001 
Hepatic TG content, % 6.59 (0.40─31.74) 0.73 (0.17─4.45) < 0.001 
Visceral fat, cm3 3304(1257─ 5743) 843 (67─3170) < 0.001 
Subcutaneous fat, cm3 4816(2216─ 9354) 1773 (284─4017) < 0.001 
VAT/SAT ratio 0.63 (0.26─1.64) 0.46 (0.13─1.23) < 0.001 
fS = fasting serum, fP = fasting plasma, TG = triglycerides, HOMA = homeostatic 
model assessment, CRP = c-reactive protein, VAT = visceral adipose tissue and  
SAT = subcutaneous adipose tissue. P values are for the difference between two 
groups. Data are presented as means (SD), median (range) or (%). 
 
In an association analysis presented in Table 7 visceral fat and hepatic TG content 
showed statistically significant positive correlations with WC, BMI, systolic and 
diastolic BP, triglycerides, fasting plasma glucose, fasting plasma insulin, HOMA 
index, subcutaneous fat and VAT/SAT ratio, whereas the correlation with HDL-
cholesterol was negative. A statistically significant, but weaker, correlation was 
found between VAT/SAT ratio and hepatic TG content. 
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Table 7. Univariate correlation coefficients between hepatic TG content, visceral fat, 
VAT/SAT ratio and cardiometabolic risk factors. Adjusted for age and smoking. 
 Hepatic TG content Visceral fat VAT/SAT ratio 
Age 0.221 0.416c 0.510c 
WC 0.607c 0.842c 0.129 
BMI 0.584c 0.807c 0.063 
Systolic BP 0.308b 0.401c 0.087 
Diastolic BP 0.413c 0.493c 0.118 
Total cholesterol 0.037 0.146 0.091 
LDL cholesterol 0.051 0.211 0.162 
HDL cholesterol - 0.321b - 0.590c - 0.286a 
TG 0.254a 0.486c 0.183 
Fasting plasma glucose 0.369b 0.445c 0.143 
Fasting serum insulin 0.508c 0.648c 0.213 
HOMA index 0.536c 0.761c 0.228a 
High-sensitivity CRP 0.229 0.373b - 0.110 
Hepatic TG content    ─ 0.779c 0.477c 
Visceral fat 0.779c    ─ 0.537c 
Subcutaneous fat 0.514c 0.764c - 0.028 
VAT/SAT ratio 0.476c 0.537c   ─ 
a p < 0.05; b p < 0.01; c p < 0.001 
In stepwise multivariable regression analyses, visceral fat proved to be an 
independent determinant of triglycerides, HDL-cholesterol, plasma glucose, serum 
insulin and HOMA index. Age and subcutaneous fat were independent predictors 
of systolic and diastolic BP; see Table 8.  
Table 8. Stepwise multivariable regression analyses 
Dependent variable Independent variable β p-value 
 Age - 0.107 0.252 
 Hepatic TG t (log) - 0.203 0.215 
Triglycerides (log) Visceral fat (log)  - 0.654 < 0.001 
 Subcutaneous fat (log) - 0.265 0.097 
 Adjusted R2   0.488 < 0.001 
 Age  0.242 0.021 
 Hepatic TG (log)  0.268 0.141 
HDL cholesterol  Visceral fat (log)  - 0.686 < 0.001 
 Subcutaneous fat (log)  - 0.098 0.584 
 Adjusted R2   0.364 < 0.001 
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 Age  0.030 0.777 
 Hepatic TG (log)  0.170 0.373 
Fasting glucose (log) Visceral fat (log)  0.411 0.002 
 Subcutaneous fat (log)  0.215 0.238 
 Adjusted R2   0.345 < 0.001 
 Age - 0.009 0.892  
  Hepatic TG (log)  0.078 0.496 
Fasting insulin (log) Visceral fat (log)  0.618 < 0.001 
 Subcutaneous fat (log)  0.291 0.011 
 Adjusted R2   0.752 < 0.001 
 Age  0.004 0.946 
 Hepatic TG t (log)  0.100 0.362 
HOMA index (log) Visceral fat (log)  0.613 < 0.001 
 Subcutaneous fat (log)  0.301 0.006 
 Adjusted R2   0.769 < 0.001 
 Age  0.328 0.001 
 Hepatic TG (log)  0.177 0.220 
Systolic BP (log) Visceral fat (log)  0.159 0.420 
 Subcutaneous fat (log)  0.452 < 0.001 
 Adjusted R2   0.358 < 0.001 
 Age  0.238 0.013 
 Hepatic TG (log)  0.187 0.189 
Diastolic BP (log) Visceral fat (log)  0.207 0.284 
 Subcutaneous fat (log)  0.534 < 0.001 
 Adjusted R2   0.379 < 0.001 
7.3 Study III 
In the total group of study participants, there were no significant distinctions 
regarding BMI, WC, systolic and diastolic BP or triglyceride concentrations 
between baseline and follow-up visits. Total cholesterol, LDL-cholesterol and 
HDL-cholesterol concentrations decreased while glucose concentration increased 
during follow-up (Table 9). All lifestyle factors assessed indicate a significant 
improvement: the number of smokers decreased, physical activity increased, and 
the number of soft fat users increased (Table 10). During the follow-up, the overall 
risk profile improved, as estimated by the CVD risk score, while the Framingham 
risk score indicated a worsening risk profile (Table 11). 
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Of the 200 men who took part in the two-year follow-up visit, data on educational 
attainment were available for 185 men. We categorised these men into three levels 
based upon their duration of formal schooling: low ≤ 9 years, n = 31 (16.8%); 
middle 10 to 12 years, n = 87 (47%); and high ≥ 13 years, n = 67 (36.2%). There 
were no statistically significant differences between the educational groups either at 
the baseline visit or at the follow-up visit in any of the clinical characteristics 
assessed (Table 9). Within the groups, some parameters improved, while others did 
not or even worsened. There was a reduction of 3.5% of total cholesterol in all 
groups. In the middle educational group, LDL-cholesterol decreased by 6.7% and 
less in the other groups. In the high educational group, triglycerides decreased 
12.9%, but in the other groups, the change was in the opposite direction and not so 
prominent. HDL-cholesterol decreased in the low educational group by 17.6%, in 
the middle educational group by 12.2% and in the high educational group by 
10.5%, respectively. The glucose concentration increased in the low and middle 
educational groups by 3.6% and in the high educational group by 5.5%, 
respectively. However, none of the changes within groups which have been 
described achieved statistical significance. In all groups, the change in BMI, WC 
and systolic and diastolic BP between visits was only marginal (Table 9). 
Regarding lifestyle characteristics at the baseline, the use of soft fat among 
participants who belonged to the low educational attainment group was 
considerably lower than among participants in the other groups. The use of soft fat 
differed statistically significantly between the groups (p = 0.019). Other lifestyle 
factors evaluated did not vary markedly between the groups at the baseline visit. 
The results from the follow-up visit showed that the users of soft fat in the groups 
are closer and there is no longer any important distinction between the groups. 
Moreover, there was no statistically significant difference between the groups in 
the other lifestyle factors investigated. For all lifestyle factors, the changes within 
groups were in a desired direction and statistically significant, except in the low 
educational attainment group, where the increase of physical activity did not reach 
a statistically significant level. The most prominent change within the group was 
the increase of users of soft fat in the low educational attainment group (Table 10). 
The overall CVD risk profile varied notably between the groups at baseline and at 
follow-up visits when assessed by the CVD risk score. At the baseline, the results 
displayed the least risk level in the high educational group. During follow-up, the 
risk level decreased in all the groups; however, it was the lowest in the high 
educational group. According to the Framingham risk score, the risk level 
60 
 
heightened during follow-up in the low and middle educational groups, while in the 
high educational group, the risk level remained unchanged (Table 11).  
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7.4 Study IV 
During the five years of follow-up, there were 230 dropouts. At the baseline, there 
were no contrasts between the dropouts and those who continued in any of the risk 
factors assessed (all p > 0.11). The dropouts had a higher CVD risk score than 
those who continued (6.4 vs. 6.1), but the disparity was not statistically significant 
(p = 0.46). The mean follow-up time was 5.1 years (SD = 0.4). The results at 
follow-up were available for 159 subjects.  
The men were divided into three groups based upon self-reported CVD monitoring 
visits during follow-up. Of these people, 34.6% (Group 1) had not visited 
healthcare providers for CVD monitoring between the baseline and follow-up, 
whereas 37.1% had made such visits at their primary healthcare centres (Group 2), 
and 28.3% had visited occupational healthcare (Group 3). Two men were followed 
up in private healthcare. For further analyses, these men were included in Group 3. 
There was minimal attendance in the group sessions provided at local healthcare 
centres as routine activities. Of the 12 men who joined the weight programme, 
seven belonged to group 2, and five, to group 3. Only one participant (group 3) 
took part in the smoking cessation programme.  
In all, a positive family history for CVD was reported by 33.1% of the subjects, 
divided by group: 18.5% of the men in Group 1, 45.5% of the men in Group 2 and 
40.3% of the men in Group 3. At the baseline, no subjects received 
antihypertensive, lipid-lowering or diabetes medication. During the follow-up, the 
medications for men in groups 2 and 3 were initiated by primary healthcare or 
occupational care physicians as follows: antihypertensive medications 40.7% and 
26.7% (p = 0.136), respectively; lipid-lowering medication 23.7% and 8.9% (p = 
0.048), respectively; and type 2 diabetes medication 10.2% and 2.2% (p = 0.110), 
respectively. 
In the total group of study participants, BMI, WC and SBP were higher at the 
follow-up than at the baseline; the change was not significant. A statistically 
significant increase was seen only in glucose concentration. The lower values in 
LDL-cholesterol, triglycerides concentrations and DBP at follow-up did not 
diverge importantly from the values at baseline, whereas the decrease in HDL-
cholesterol concentration reached statistical significance. The total cholesterol 
remained unchanged (Table 12). In all, for the three lifestyle factors evaluated, the 
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change was statistically significant (Table 13). The overall risk profile indicated 
improvement during the follow-up with both risk tools. The change was 
statistically significant with the CVD risk score but not with the SCORE Chart 
(Table 14). 
None of the risk factors analysed indicated statistically significant disparities 
between the groups either at baseline or at follow-up (Table 12). Within the groups, 
the values of some parameters indicated improvement, while others worsened. A 
statistically significant change in the worse direction was seen in systolic and 
diastolic BP and in total cholesterol concentration in group 1. A statistically 
significant decrease in HDL cholesterol concentration was seen in all groups, with 
an increase in glucose concentrations in groups 1 and 3, respectively. The lowering 
of DBP and LDL cholesterol concentration in group 2 was the only statistically 
significant improvement among the risk factors (Table 12).  
Even though lifestyle factors diverged to some extent between groups, there were 
no statistically significant differences between the groups in any of the lifestyle 
factors assessed, either at baseline or at follow-up. In all groups, within-group 
changes in all lifestyle factors assessed proved to be desirable and were statistically 
significant. The most prominent change was the increased number of users of soft 
fat (Table 13). 
The overall CVD risk profile did not vary importantly between the groups at 
baseline regardless of the method used, the CVD risk score or the SCORE Chart. 
The changes in the risk profile within individual groups during the follow-up led to 
a statistically significant difference between the groups. In group 1, the risk level 
improved marginally during the follow-up when assessed by CVD risk score, while 
by SCORE Chart, the alteration in the risk level was reversed. In groups 2 and 3, 
there was a substantial decrease in the risk during the follow-up, as assessed by 
both risk scores; however, the change was statistically significant only by the CVD 
risk score (Table 14). The reduction of the risk level remained statistically 
significant even when analyses were limited to participants receiving no cardio-
metabolic medications. 
 
67
 
 
T
ab
le
 1
2.
 C
lin
ic
al
 c
ha
ra
ct
er
is
ti
cs
 a
t b
as
el
in
e 
an
d 
fo
llo
w
-u
p 
ac
co
rd
in
g 
to
 r
is
k 
co
m
m
un
ic
at
io
n 
vi
si
ts
 d
ur
in
g 
 
fo
llo
w
-u
p 
 
R
is
k 
co
m
m
un
ic
at
io
n 
vi
si
ts
 d
ur
in
g 
fo
llo
w
-u
p 
 
 
 
 
N
o 
vi
si
ts
 
P
ri
m
ar
y 
ca
re
 
O
cc
up
at
io
na
l c
ar
e 
 
A
ll 
 
 
n 
=
 5
5 
n 
=
 5
9 
n 
=
 4
5 
P
 
va
lu
e 
n 
=
 1
59
 
P
 v
al
ue
 b
 
B
M
I 
kg
/m
2 
 
 
 
 
 
 
 
B
as
el
in
e 
29
.1
 (
4.
5)
 
30
.2
 (
6.
6)
 
29
.0
 (
4.
3)
 
0.
43
4 
29
.5
 (
5.
3)
 
 
F
ol
lo
w
-u
p 
29
.7
 (
4.
5)
 
30
.6
 (
7.
2)
 
29
.9
 (
4.
6)
 
0.
65
0 
30
.1
 (
5.
7)
 
0.
00
1 
95
%
 C
I 
-0
.4
 to
 -
1.
2 
-0
.2
 to
 1
.1
 
0.
3 
to
 1
.5
 
 
0.
3 
to
 1
.0
 
 
W
C
 c
m
 
 
 
 
 
 
 
B
as
el
in
e 
10
1.
7 
(1
2.
0)
 
10
5.
9 
(1
5.
3)
 
10
3.
1 
(1
0.
8)
 
0.
24
4 
10
3.
7 
(1
3.
1)
 
 
F
ol
lo
w
-u
p 
10
3.
0 
(1
2.
1)
 
10
5.
7 
(1
7.
3)
 
10
4.
8 
(1
2.
4)
 
0.
40
2 
10
4.
5 
(1
4.
2)
 
0.
12
8 
95
%
 C
I 
-0
.6
 to
 3
.2
 
-2
.0
 to
 1
.5
 
-0
.4
 to
 3
.8
 
 
-0
.2
 to
 1
.9
 
 
S
B
P
 m
m
H
g 
 
 
 
 
 
 
B
as
el
in
e 
13
6.
6 
(1
5.
1)
 
14
1.
5 
(1
8.
7)
 
14
0.
0 
(1
5.
9)
 
0.
27
8 
13
9.
4 
(1
6.
7)
 
 
F
ol
lo
w
-u
p 
14
4.
2 
(1
8.
6)
 
13
7.
7 
(1
4.
9)
 
14
2.
4 
(1
4.
7)
 
0.
09
2 
14
1.
4 
(1
6.
4)
 
0.
15
6 
95
%
 C
I 
3.
6 
to
 1
1.
7 
-8
.0
 to
 0
.4
 
-2
.8
 to
 7
.5
 
 
-0
.7
 to
 4
.5
 
 
D
B
P 
m
m
H
g 
 
 
 
 
 
 
B
as
el
in
e 
88
.6
 (
9.
5)
 
93
.9
 (
12
.8
) 
92
.6
 (
9.
9)
 
0.
02
6 
91
.7
 (
11
.1
) 
 
F
ol
lo
w
-u
p 
92
.9
 (
10
.6
) 
89
.0
 (
8.
9)
 
91
.8
 (
9.
8)
 
0.
10
3 
91
.2
 (
9.
9)
 
0.
57
0 
95
%
 C
I 
1.
7 
to
 6
.9
 
-8
.0
 to
 -
1.
8 
-4
.5
 to
 2
.8
 
 
-2
.4
 to
 1
.3
 
 
T
ot
al
-C
 
 
 
 
 
 
 
B
as
el
in
e 
5.
6 
(1
.0
) 
5.
6 
(1
.3
) 
5.
5 
(1
.0
) 
0.
96
3 
5.
5 
(1
.1
) 
 
F
ol
lo
w
-u
p 
5.
8 
(0
.9
) 
5.
3 
((
1.
0)
 
5.
4 
(1
.1
) 
0.
83
0 
5.
5 
(1
.1
) 
0.
66
6 
95
%
 C
I 
0.
0 
to
 0
.4
 
-0
.6
 to
 0
.1
 
-0
.3
 to
 0
.2
 
 
-0
.2
 to
 0
.1
 
 
 
 
 
 
 
 
 
68
 
 
L
D
L
-C
 
 
 
 
 
 
 
B
as
el
in
e 
3.
26
 (
0.
83
) 
3.
20
 (
0.
99
) 
3.
27
 (
0.
88
) 
0.
84
1 
3.
24
 (
0.
90
) 
 
F
ol
lo
w
-u
p 
3.
31
 (
0.
78
) 
2.
94
 (
0.
85
) 
3.
23
 (
0.
94
) 
0.
11
7 
3.
15
 (
0.
86
) 
0.
15
3 
95
%
 C
I 
-0
.1
2 
to
 0
.2
2 
-0
.5
0 
to
 -
0.
03
 
-0
.3
1 
to
 0
.2
2 
 
-0
.2
2 
to
 0
.0
3 
 
H
D
L
-C
 
 
 
 
 
 
 
B
as
el
in
e 
1.
57
 (
0.
46
) 
1.
52
 (
0.
36
) 
1.
41
 (
0.
34
) 
0.
14
9 
1.
51
 (
0.
39
) 
 
F
ol
lo
w
-u
p 
1.
42
 (
0.
34
) 
1.
36
 (
0.
40
) 
1.
29
 (
0.
34
) 
0.
26
2 
1.
36
 (
0.
39
) 
<
0.
00
1 
95
%
 C
I 
-0
.2
2 
to
 -
0.
09
 
-0
.2
4 
to
 -
0.
07
 
-0
.1
9 
to
 -
0.
07
 
 
-0
.1
9 
to
 -
0.
11
 
 
T
G
 
 
 
 
 
 
 
B
as
el
in
e 
1.
72
 (
1.
11
) 
2.
14
 (
2.
51
) 
2.
03
 (
1.
82
) 
0.
49
8 
1.
96
 (
1.
92
) 
 
F
ol
lo
w
-u
p 
1.
75
 (
1.
04
) 
1.
72
 (
0.
96
) 
1.
88
 (
2.
86
) 
0.
88
2 
1.
77
 (
1.
72
) 
0.
19
0 
95
%
 C
I 
-0
.2
6 
to
 0
.3
1 
-1
.0
7 
to
 0
.2
2 
-0
.6
0 
to
 0
.3
1 
 
-0
.4
7 
to
 0
.0
9 
 
G
lu
co
se
 
 
 
 
 
 
 
B
as
el
in
e 
5.
5 
(0
.6
) 
5.
7 
(0
.6
) 
5.
6 
(0
.5
) 
0.
12
3 
5.
6 
(0
.6
) 
 
F
ol
lo
w
-u
p 
5.
9 
(0
.8
) 
5.
8 
(0
.8
) 
5.
9 
(0
.7
) 
0.
86
3 
5.
9 
(0
.8
) 
<
0.
00
1 
95
%
 C
I 
0.
2 
to
 0
.5
 
-0
.1
 to
 0
.3
 
0.
1 
to
 0
.4
 
 
0.
1 
to
 0
.3
 
 
D
at
a 
ar
e 
m
ea
ns
 (
S
D
).
 a 
P
 v
al
ue
s 
ar
e 
a 
te
st
 o
f 
eq
ua
li
ty
 b
et
w
ee
n 
gr
ou
ps
. b
 P
 a
re
 v
al
ue
s 
fo
r 
th
e 
pa
ir
ed
  
di
ff
er
en
ce
. B
M
I 
=
 b
od
y 
m
as
s 
in
de
x,
 W
C
 =
 w
ai
st
 c
ir
cu
m
fe
re
nc
e,
 S
B
P
 =
 s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e,
  
D
B
P
 =
 d
ia
st
ol
ic
 b
lo
od
 p
re
ss
ur
e,
 T
ot
al
-C
 =
 to
ta
l c
ho
le
st
er
ol
 in
 m
m
ol
/l
, L
D
L
-C
 =
 lo
w
-d
en
si
ty
  
li
po
pr
ot
ei
n 
ch
ol
es
te
ro
l i
n 
m
m
ol
/l
, H
D
L
-C
 =
 h
ig
h-
de
ns
it
y 
li
po
pr
ot
ei
n 
ch
ol
es
te
ro
l i
n 
m
m
ol
/l
, T
G
 =
 tr
ig
ly
ce
ri
de
s 
 
in
 m
m
ol
/l
, G
lu
co
se
 in
 m
m
ol
/l
. 9
5%
 C
I 
ar
e 
fo
r 
ch
an
ge
s 
of
 m
ea
ns
 b
et
w
ee
n 
ba
se
lin
e 
an
d 
fo
llo
w
-u
p 
vi
si
ts
. 
 
69
 
 
T
ab
le
 1
3.
 L
if
es
ty
le
 c
ha
ra
ct
er
is
tic
s 
at
 b
as
el
in
e 
an
d 
fo
ll
ow
-u
p 
ac
co
rd
in
g 
to
 r
is
k 
co
m
m
un
ic
at
io
n 
vi
si
ts
 d
ur
in
g 
fo
llo
w
-u
p 
  
R
is
k 
co
m
m
un
ic
at
io
n 
vi
si
ts
 d
ur
in
g 
fo
llo
w
-u
p 
 
 
 
 
N
o 
vi
si
ts
 
P
ri
m
ar
y 
ca
re
 
O
cc
up
at
io
na
l c
ar
e 
 
 
A
ll 
 
 
n 
=
 5
5 
n 
=
 5
9 
n 
=
 4
5 
P
 v
al
ue
 a  
n 
=
 1
59
 
P
 v
al
ue
 b
 
S
m
ok
in
g%
 
 
 
 
 
 
 
B
as
el
in
e 
63
.6
 
50
.8
 
51
.1
 
 
55
.3
 
 
F
ol
lo
w
-u
p 
50
.9
 
37
.3
 
40
.0
 
0.
30
9 
42
.8
 
<
0.
00
1 
95
%
 C
I 
-2
3.
9 
to
 -
0.
8 
-2
3.
4 
to
 -
3.
1 
-2
4.
8 
to
 3
.5
 
 
-1
9.
2 
to
 -
5.
7 
 
P
A
 ≥
 9
0 
m
in
/w
k%
 
 
 
 
 
 
 
B
as
el
in
e 
36
.4
 
22
.0
 
28
.9
 
0.
24
1 
28
.9
 
 
F
ol
lo
w
-u
p 
60
.0
 
55
.9
 
53
.3
 
0.
79
2 
56
.6
 
<
0.
00
1 
95
%
 C
I 
9.
5 
to
 3
6.
2 
18
.9
 to
 4
6.
6 
4.
7 
to
 4
1.
6 
 
18
.6
 to
 3
6.
0 
 
U
se
rs
 o
f 
so
ft
 f
at
%
 
 
 
 
 
 
 
B
as
el
in
e 
21
.8
 
22
.0
 
11
.1
 
0.
27
7 
18
.9
 
 
F
ol
lo
w
-u
p 
72
.7
 
84
.7
 
73
.3
 
0.
24
6 
77
.4
 
<
0.
00
1 
95
%
 C
I 
35
.5
 to
 6
2.
3 
46
.6
 to
 7
3.
6 
45
.5
 to
 7
3.
9 
 
49
.7
 to
 6
5.
5 
 
P
A
 =
 p
hy
si
ca
l a
ct
iv
it
y.
 a
 P
 v
al
ue
s 
ar
e 
as
se
ss
ed
 f
or
 th
e 
te
st
 o
f 
eq
ua
li
ty
 b
et
w
ee
n 
gr
ou
ps
. b
 P
 a
re
 v
al
ue
s 
fo
r 
pa
ir
ed
 d
if
fe
re
nc
e.
 
95
%
 C
I 
si
gn
if
y 
ch
an
ge
s 
of
 m
ea
ns
 b
et
w
ee
n 
ba
se
li
ne
 a
nd
 f
ol
lo
w
-u
p 
vi
si
ts
. 
  
 
70
 
 
T
ab
le
 1
4.
 R
is
k 
sc
or
es
 a
t b
as
el
in
e 
an
d 
fo
llo
w
-u
p 
ac
co
rd
in
g 
to
 r
is
k 
co
m
m
un
ic
at
io
n 
vi
si
ts
 d
ur
in
g 
fo
llo
w
-u
p 
 
R
is
k 
co
m
m
un
ic
at
io
n 
vi
si
ts
 d
ur
in
g 
fo
llo
w
-u
p 
 
 
 
 
N
o 
vi
si
ts
 
P
ri
m
ar
y 
ca
re
 
O
cc
up
at
io
na
l c
ar
e 
 
 
A
ll 
 
 
n 
=
 5
5 
n 
=
 5
9 
n 
=
 4
5 
P
 v
al
ue
 a  
15
9 
P
 v
al
ue
 b
 
C
V
D
 r
is
k 
sc
or
e 
 
 
 
 
 
 
B
as
el
in
e 
6.
0 
(1
.7
) 
6.
1 
(1
.7
) 
6.
0 
(1
.4
) 
0.
89
8 
6.
1 
(1
.6
) 
 
F
ol
lo
w
-u
p 
5.
9 
(2
.2
) 
4.
8 
(2
.3
) 
5.
4 
(2
.2
) 
0.
02
7 
5.
4 
(2
.3
) 
<
0.
00
1 
95
%
 C
I 
-0
.5
 to
 0
.4
 
-1
.9
 to
 -
0.
8 
-1
.4
 to
 0
.1
 
 
-1
.1
 to
 -
0.
4 
 
S
C
O
R
E
 C
ha
rt
 
 
 
 
 
 
 
B
as
el
in
e 
4.
7 
(1
.7
) 
5.
1 
(2
.2
) 
4.
8 
(2
.2
) 
0.
59
4 
4.
9 
(2
.1
) 
 
F
ol
lo
w
-u
p 
5.
2 
(2
.3
) 
4.
0 
(1
.9
) 
4.
3 
(2
.1
) 
0.
01
0 
4.
5 
(2
.2
) 
0.
06
0 
95
%
 C
I 
-0
.1
 to
 1
.1
 
-1
.6
 to
 -
0.
68
 
-1
.3
 to
 0
.3
 
 
-0
.7
 to
 0
.0
 
 
D
at
a 
ar
e 
m
ea
ns
 (
S
D
).
 a 
P
 v
al
ue
s 
ar
e 
fo
r 
te
st
in
g 
th
e 
eq
ua
lit
y 
be
tw
ee
n 
gr
ou
ps
. b
 P
 v
al
ue
s 
ar
e 
fo
r 
te
st
in
g 
th
e 
pa
ir
ed
  
di
ff
er
en
ce
. C
V
D
 r
is
k 
sc
or
e 
is
 a
 m
od
if
ie
d 
ve
rs
io
n 
of
 th
e 
N
or
th
 K
ar
el
ia
 p
ro
je
ct
 r
is
k 
to
ol
. S
co
re
 C
ha
rt
:  
C
V
D
 r
is
k 
ex
tr
ap
ol
at
ed
 to
 a
ge
 6
0 
by
 S
co
re
 E
ur
op
ea
n 
L
ow
 R
is
k 
C
ha
rt
 (3
) . 
95
%
 C
I 
ar
e 
fo
r 
ch
an
ge
s 
of
 m
ea
ns
  
be
tw
ee
n 
ba
se
li
ne
 a
nd
 f
ol
lo
w
-u
p 
vi
si
ts
. 
71 
 
8 DISCUSSION 
8.1 Study I 
Abdominal obesity, often expressed as increased WC, is an independent predictor 
of cardiometabolic risk factors, such as dyslipidaemia, hyperglycaemia and 
hypertension (165, 166) as well as CVDs (167,168) and type 2 diabetes (169,170). 
In our study, which included a community-based sample of 196 middle-aged men, 
109 had a positive risk status, meaning either a CVD risk score ≥ 4.5 or a 
FINDRISC score ≥ 7 or both, hereinafter called a positive risk. A WC of ≥ 94 cm 
correctly detected 92 men (true positives) and correctly left undetected 68 men 
(true negatives). When calculated on the basis of these figures, the sensitivity, 
specificity, and positive and negative predictive values of the test were: 84.4% 
(95% CI 76.4% to 90.0%), 78.2% (95% CI 68.4% to 85.5%), 82.9% (95% CI 
74.8% to 88.8%) and 80.8% (95% CI 70.3% to 87.1%), respectively.  
The prevalence of a positive risk in the study’s population is 109/196, that is 
55.6%. Applying this test in another population depends on the prevalence of the 
positive risk in that population leading to other predictive values. Generally, using 
the same test in a population with a higher prevalence increases the positive 
predictive value, and the negative predictive value decreases, respectively. 
Conversely, using the same test in a population with a lower prevalence decreases 
the positive predictive value; the negative predictive value increases, respectively 
(171). Generalisability also requires considering that the relationships between WC 
and health outcomes are affected by variables such as sex, ethnicity and age (172). 
Generally, a high PPV and high NPV are desirable test characteristics, providing 
that false positives and false negatives are minimised (171). Our test meets this 
condition. With a PPV of 82.9% and an NPV of 80.8%, the number of false 
positives and false negatives was 19 and 17, respectively. 
The lower the number of false positives, the less the unnecessary load on the 
healthcare system. Moreover, because men displaying false negatives are not 
necessarily guided to counselling, a lower number is desirable.  
The medians of the CV risk and diabetes scores were at a lower level (3.5 for CVD 
risk score and 6 for FINDRISC) than the thresholds used. Using the thresholds 
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levels of ≥ 4.5 and ≥ 7, we avoided the possibility that only one single risk factor 
could lead to a positive risk level in the test. The CVD risk score and FINDRISC 
consist of a total of 10 cardio-metabolic risk factors. The highest single diabetes 
risk score (5 points) is obtained by an individual who at least occasionally has an 
elevated glucose level or who has a first-degree relative with diabetes. The highest 
single CVD Risk Score (4 points) is obtained by heavy smoking (at least 30 
cigarettes per day) or by having a total cholesterol ≥ 8.5 mmol/l. 
As the outcome variable is set to a relatively low level, the test can identify subjects 
in the phase where lifestyle modifications still have an impact on major risk 
factors. Restoring risk factors to their former levels is increasingly difficult in 
societies today. Among middle-aged men, the weight loss achieved within five 
years significantly reduced their risk for CVD over the subsequent 15 years but 
only in considerably overweight younger men (173). Even in adolescence (15 years 
of age), CVD risk factors are at higher level among those with a WC ≥ 75th 
percentiles than among those with a WC ≤ 25th percentiles (174). A favourable risk 
profile early in life is associated with better health outcomes later in life (175). Risk 
factor levels in adolescence have an important role in the pathogenesis of CHD 
(176). It is questionable whether a risk assessment is correctly timed at middle-age; 
however, it does follow the recommendations of institutional authors (134).  
In conclusion, a WC measurement is an easy way to obtain reliable information on 
cardio-metabolic risks. A cut-off point for a WC of ≥ 94 cm proved to be a good 
screening test to detect those with increased risk for future CVD and/or type 2 
diabetes among 40-year-old Finnish men. There are limitations for expanding this 
test in other populations and in women; however, it can be used more widely in 
screening for cardio-metabolic risks in middle-aged Finnish men. The 
implementation of this screening method challenges the whole primary healthcare 
team, including nurses and practitioners. Everyone is responsible for recording 
their results in the health record of the healthcare customer as a starting point for 
the further evaluation of cardio-metabolic risks and initiate, if necessary, lifestyle 
counselling practices. 
8.2 Study II 
The use of imaging techniques, such as computer tomography or magnetic 
resonance imaging, has demonstrated that an excess accumulation of visceral 
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adipose tissue is associated with an atherogenic lipoprotein profile independent of 
BMI and SAT (177). It has been reported that an increase in VAT volume is 
associated with adverse changes in CVD risk factors, including triglycerides, HDL-
cholesterol, blood glucose, BP and metabolic syndrome (178,179, 180) and an increased 
risk for CVD (181) and type 2 diabetes (182, 183).  
We used the definition of MetS (158) to divide the study population into two groups. 
The two groups diverged notably according to various cardiometabolic risk factors, 
as expected. Besides the risk factors included in the definition of MetS, total 
cholesterol, LDL-cholesterol, insulin and the HOMA index revealed notably higher 
values among those with MetS than among those without MetS. This also applies 
to hepatic triglyceride content as well as visceral and subcutaneous fat volumes. 
The association between hepatic TG content and visceral fat was significant 
respecting cardio-metabolic risk factors. The associations were stronger with 
visceral fat than with hepatic TG content. These findings confirm the previous 
results of Liu et al. (184). Of all of the risk factors studied, the strongest association 
observed was that between visceral fat and WC. Other risk factors revealing a 
statistically significant association with visceral fat were age, BMI, systolic and 
diastolic BP, HDL-cholesterol, triglycerides, fasting plasma glucose, fasting 
plasma insulin and HOMA index.  
In the 1990s, the authors of a study in which abdominal visceral adiposity was 
verified by computer tomography proposed the use of WC as an anthropometric 
equivalent to visceral adiposity (103). The study demonstrated a high correlation 
between WC and plasma triglycerides and HDL-cholesterol levels, fasting glucose, 
findings from a glucose challenge test and insulin levels. In a study including 185 
healthy men (not under treatment for CHD, dyslipidaemia, diabetes or endocrine 
disorders), a specific phenotype called the hyper-triglyceridemic waist was 
proposed and defined as follows: WC ≥ 90 cm and fasting triglyceride level ≥ 2.0 
mmol/l. A WC ≥ 90 cm distinguishes men with hyperinsulinemia and increased 
apolipoprotein B concentration from those with normal concentrations of both 
variables, whereas a fasting triglyceride concentration ≥ 2.0 mmol/l identifies men 
with a small, dense LDL particles. The authors exhibited the functionality of the 
concept in another sample of 287 men with and without coronary artery disease 
(CAD) verified by angiography. Men with both elevated WC and TG levels were at 
increased risk of CAD compared with men with low WC and low TG levels (185). 
The relationship between the hyper-triglyceridemic-waist phenotype and CAD has 
also been confirmed in a prospective population study. Compared to participants 
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with a WC < 90 cm and TG < 2.0 mmol/l, the risk for CAD increased in 
combinations of these variables as follows: participants with a WC < 90 cm and 
TG ≥ 2.0 mmol/l, participants with a WC ≥ 90 cm and TG < 2.0 mmol/l, and WC ≥ 
90 cm and TG ≥ 2.0 mmol/l. The lattermost always had a higher risk (186). 
In our cross-sectional study, the regression analyses confirm that visceral fat is an 
independent predictor of triglycerides, HDL-cholesterol, fasting plasma glucose 
and insulin, and HOMA index. Regardless of the strong association of visceral fat 
with diastolic and systolic BP, it does not indicate predictive power for 
hypertension, unlike subcutaneous fat. However, there are (prospective) studies 
whereby visceral fat alone (187) and both visceral and subcutaneous fat have been 
shown to predict hypertension in an overweight population (180). 
In conclusion, an initial risk assessment can be based on a single anthropometric 
measurement, WC. However, even though WC predicts traditional cardiovascular 
risk factors, it cannot be used on its own to properly assess the risk of an 
individual. 
8.3 Study III 
Socioeconomic status (SES) is one of the strongest predictors of (general) 
morbidity and mortality (188, 189). SES is a complex phenomenon often 
conceptualised as a combination of financial, occupational and educational 
influences (190). Educational level is an eligible determinant to indicate inequality in 
the morbidity of type 2 diabetes (191, 192), the incidence of CVD (193) and the 
prevalence of CVD risk factors (190,194,195). Educational attainment has been 
proposed as a determinant of SES unless the study’s hypothesis specifies which 
dimension of SES should be chosen (190). 
In today´s society, social inequality can be seen, for example in unhealthy lifestyles 
in people with lower educational levels. Among the adult population in Finland, the 
smoking prevalence has declined notably over decades, but the variations between 
socioeconomic groups are still considerable. Among low, middle and highly 
educated people, the smoking prevalence was 17%, 11% and 6%, respectively, in 
2017 (196). 
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During the study period of the present work (2006 to 2008), the smoking 
prevalence was approximately 35% among middle-aged men in Finland (197,198) and 
about 55% among the subjects in this study. 
Of the study’s participants, the proportion of smokers was highest in the low SES 
group, both at baseline and at follow-up. Although the proportion of smokers 
decreased in all groups during the follow-up period, the change was statistically 
significant only in the high SES group. After an 8.9% reduction from the baseline, 
the smoking prevalence was still 42%, which was higher than in the male 
population of the same age. The aim of the intervention in this study was a more 
comprehensive change in overall lifestyle, not just targeting smoking. 
The success of smoking cessation is less likely among those with low education. 
The results of a study following a birth cohort through adulthood demonstrated that 
the lower educated had fewer short-term and long-term attempts to quit smoking 
and were less likely to succeed than their higher educated counterparts (199). 
Cigarette consumption is greater and dependence stronger among the less educated 
than among highly educated smokers (200). 
Leisure-time physical activity is known to reduce the risk of CVD and type 2 
diabetes (201). A protective effect against cardiovascular death was seen even at a 
light level of physical activity, independent of traditional cardio-metabolic risk 
factors. Daily, brisk walking of at least 30 minutes substantially reduces the risk of 
type 2 diabetes (202). 
In our study, an increase of leisure-time physical activity was seen in all SES 
groups. The change during the follow-up was greater in the low and middle 
educational attainment groups than in the high educational attainment group. In the 
low educational attainment group, the change did not reach statistical significance. 
The general national goal for physical activity during the study was moderate to 
vigorous physical activity of at least 90 minutes per week. Notably, many men 
exceeded this level with an activity of 150 to 180 minutes per week. Despite the 
increase in physical activity in the study’s groups, the activity level remained much 
lower than in the general male population of the same age, as seen in a national 
survey in which 55% in 2006 and 60% in 2008 were practising moderate to 
vigorous physical activity at least two to three times per week (197,198).  
The use of unsaturated fat differed considerably between the groups at baseline. 
The intervention supported a significant increase in the use of unsaturated fat in all 
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groups. At the follow-up visit, independent of the education level, half of the 
participants reported that they had replaced saturated fat with unsaturated fat. The 
change was statistically significant in all groups. Among Finnish men of an age 
similar to the study’s participants’, 63% used margarine on bread, and 48% utilised 
vegetable oil for cooking in 2006. The corresponding figures were 65% and 51% in 
2008 (197,198).  
We observed that these middle-aged men with an elevated risk for CVD improved 
their lifestyles. The change was seen in all lifestyle factors assessed and in all SES 
groups. However, when focusing upon risk factors such as BMI, WC and BP, no 
improvement was observed. Alterations in lipoproteins can be observed in relation 
to changes in dietary fat ratios and presumed increase in intake of carbohydrates to 
compensate for the reduced intake of saturated fat. When part of dietary saturated 
fat is replaced by carbohydrates, triglyceride concentration increases, and HDL-
cholesterol concentration decreases (203). Elevated total carbohydrate intake causes 
the same changes in triglyceride and HDL-cholesterol concentrations (204). The 
partial replacement of dietary saturated fat with polyunsaturated fat reduces total 
and LDL-cholesterol concentrations (203). When part of dietary saturated fat is 
replaced with monounsaturated fat, the effects on lipoproteins are almost the same 
as when replaced with polyunsaturated (205). All these fit well with our findings. In 
all groups, the proportion of users of unsaturated fat increased, and total, LDL- and 
HDL-cholesterol levels decreased. Unlike other groups, triglyceride levels declined 
in the high educational attainment group only. This can be seen as the result of 
better-controlled carbohydrate intake, which could also be associated with a slight 
decline in BMI in this group. 
In all groups, fasting glucose concentrations tended to increase slightly, which can 
be interpreted as a normal increase in fasting glucose observed in association with 
increased age (206,207). We estimated the CVD risk of the study’s participants with 
the CVD risk score and the Framingham risk score (FRS). Both scores can evaluate 
a CVD risk profile, representing an RR. The FRS is also suitable for predicting the 
10-year risk of a CVD event. The positive impact of health counselling on the risk 
profile at all levels of educational attainment was seen at follow-up visits in the 
CVD risk score, while the FRS did not detect any change in the risk profile. A 
more sensitive feature of the CVD risk score compared to the FRS is probably 
partially because the CVD risk score incorporates a physical activity component 
and smoking is further assessed in nine categories, while the FRS has only two 
categories of smoking. 
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In conclusion, the present study showed that lifestyle counselling is feasible among 
40-year-old men with an elevated risk for CVD. Regardless of the level of 
education, the impact of counselling on the CVD risk profile was substantial. From 
a practical perspective, our findings stress the importance of using the CVD risk 
profile to guide health counselling instead of only examining individual risk 
factors. 
8.4 Study IV 
Both randomised controlled trials and observational studies have shown that 
lifestyle counselling has a positive impact on CVD risk factors among high-risk 
people, although the results from a range of studies are inconsistent. In short-term 
studies comparing intensive lifestyle support with the usual care have successfully 
reduced risk when implemented in primary healthcare (208,209,210) and occupational 
healthcare (211,212). In the literature, there are also studies where lifestyle counselling 
did not succeed in improving the risk profile in short-term (213) and long-term (214) 
randomised studies. 
In our research, all men comprised a uniformly high CVD risk group. Attitudes 
towards risk status varied considerably. An awareness of the elevated risk was 
inadequate to motivate all individuals to participate in risk factors monitoring 
visits. A notable part, more than one-third of the participants, did not attend a risk 
factor control visit between baseline and follow-up visits, whereas almost two-
thirds spontaneously sought risk-factor monitoring during follow-up at either local 
healthcare centres or occupational healthcare. One distinctive background feature 
among the participants was a positive family history of CVD. A positive family 
history was more than twice as common among the participants who sought risk 
factor monitoring during follow-up. 
A physician’s recommendations were more effective among those who had a 
positive family history of CVD, as they were more likely to report preventive 
actions, having cholesterol measured and the use of medication. However, reports 
of lifestyle changes were less frequent (215). Furthermore, physicians’ 
recommendations have been found to be associated with a higher likelihood of 
reported changes in diet and physical activity (216). Family history can be used to 
personalise the health message and thereby enhance the individual’s motivation to 
adopt a healthy lifestyle. However, the evidence of the effectiveness of this activity 
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is very limited (217). A family history of premature CHD is of great importance. At 
45 years of age, men with a family history of premature CHD had a 56% higher 
lifetime risk for CVD mortality compared to men without a family history of 
premature CHD (218). 
In the present study, we observed that risk-factor monitoring visits with primary 
healthcare and occupational healthcare providers led to desirable changes in 
lifestyle factors and lower CVD risk scores. Additionally, some cardio-metabolic 
risk factors improved. Blood pressure and lipids were better controlled among 
those who continued visits to their primary healthcare centre. It must be considered 
that the group continuing in primary healthcare benefited from more active 
treatment, as they received more cardio-protective medications than did those who 
received treatment at their occupational healthcare. In both groups that continued 
risk factor control visits, their overall risk status improved when they were assessed 
by the CVD risk score and the SCORE Chart. For those without such a visit, no 
improvement was seen, despite self-reported improvements in all lifestyle factors 
assessed. When evaluating the sub-population, that is men without cardio-
protective medications that were followed up in primary healthcare, lifestyle 
changes alone significantly decreased their overall risk, as assessed with the CVD 
risk score and the SCORE Chart. 
As the initial baseline risk assessment and health counselling sessions took place in 
primary healthcare centres, nurses and physicians in these centres were likely better 
prepared to guide the participants.  
In all lifestyle factors assessed, the improvement was statistically significant in all 
groups. For comparison, among Finnish men, smoking prevalence was 24% in 
2006 and 22% in 2011. Regarding physical activity, moderate to vigorous intensity 
exercise at least two to three times per week was 63% in 2006 and 67% in 2011, 
and consumption of unsaturated fat was 64% in 2006 and 60% in 2011 (219, 220). At 
the follow-up, the prevalence of smoking remained among study participants twice 
as high as in the general male population, but the decrease was distinct. Study 
subjects almost reached the level of physical activity of the general male population 
at follow-up, even though they started from a much lower level at baseline. Despite 
the study’s participants’ minor consumption of unsaturated fat at baseline, their use 
exceeded that of the general male population at follow-up. 
Risk assessment methods are available to calculate global short-term (generally 10 
years) CVD risk estimates. These methods are based on established CVD risk 
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factors, including age, hypertension, lipids and smoking. A new method has been 
published based on lifestyle, including smoking, BMI, physical activity, dietary 
intake and alcohol consumption. This method is called the Healthy Heart Score 
(HHS), and it was developed to serve as a tool for the long-term prevention of 
CVD. It is especially applicable for a population without traditional risk factors 
(usually the younger population), that is a screening tool for primordial prevention 
(221).  
The Special Turku Coronary Risk Factor Intervention Project for Children (STRIP) 
study showed that adherence to the AHA’s ideal cardiovascular health concept (222) 
throughout childhood predicted vascular health in adolescence (223). Although it is 
desirable to avoid risky behaviours and risk factors in adolescence, there is a 
window of opportunity for intervention in the transition from youth to adulthood to 
modify one’s trajectory from high risk in adolescence to low risk in adulthood (224). 
In a study of young women, a higher HHS at baseline was associated with a 
significantly greater risk of developing risk factors such as diabetes, hypertension 
and hypercholesterolaemia during 20 years of follow-up (225). A follow-up study of 
two middle-aged cohorts (women between 1984 and 2010 and men between 1986 
and 2010) proved that participants with HHS in the fifth versus the first quintile 
had significantly greater risk of death due to CHD, stroke and several cancers (226). 
We compared the risk factor status of our study’s participants to the results of a 
U.S. population survey, which estimated lifetime risk for CVD at age 50 and 
classified CVD risk into low and high categories, according to BP, total 
cholesterol, diabetes and smoking status 227. We found that, at a follow-up visit, 12 
participants of those 59 who achieved a CVD risk score level of < 4.5 had a low 
lifetime risk for CVD and all the others had a high lifetime risk. According to the 
aforementioned survey, men with an SBP between 140 mmHg and 159 mmHg or 
DBP between 90 mmHg and 99 mmHg or total cholesterol between 200 mg/dl 
(5.18 mmol/l) and 239 mg/dl (6.19 mmol/l) have a lifetime risk for CVD of 46%. 
The lifetime risk for CVD increased to 50% when one of these cut-offs was 
exceeded and to 69% when two of these cut-offs were exceeded or if individuals 
have diabetes or were current smokers. Among our study’s participants, 27% had a 
lifetime risk of 46%, 40.9% had a lifetime risk of 50%, and 24.5% had a lifetime 
risk of 69%.  
During the study’s period, according to SCORE Chart, none of the participants in 
the present study exceeded a high short-term risk level. At the follow-up visit, 
80 
 
according to the SCORE relative risk table, 17.1% of the study’s participants had a 
risk equal to a person with all risk factors at an optimal level, while 16.5% had a 
five-time higher risk than that. The rest were in between. 
The European Guidelines do not recommend that the decision for lifelong 
preventive treatment be based on the lifetime risk in people with low short-term 
risk. Such a situation should signal the need for active lifestyle advice and the 
awareness that starting drug treatments may need to be considered later in life (134). 
In conclusion, the modification of non-optimal lifestyles is a key issue in the 
primordial and primary prevention of CVD. The evaluation of lifestyles for 
preventive purposes is important at an early age and, at the latest, in middle age. 
Maintaining optimal lifestyles will prevent risk factors from increasing to a 
detrimental level or at least postpone it. From middle age onward, it is necessary to 
control cardio-metabolic risk factors alongside lifestyle monitoring. A positive 
family history of premature CVD should act as an alarm throughout the lifespan for 
all preventive actions. 
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9 STRENGTHS AND LIMITATIONS 
Although a randomised controlled study design is considered methodologically 
more advanced than an observational study design, we decided to choose an 
observational design for our research. This is primarily because for ethical reasons; 
it would have been unethical to refuse health counselling from the control group. 
The homogeneity of the participants’ age, gender and ethnicity can be seen as one 
of the strengths of our study. In addition, the validity of the results is supported by 
the fact that all participants underwent the same risk factor assessment and received 
the same health counselling during the baseline visit. Furthermore, another main 
strength of our study can be considered to be the natural course of follow-up. That 
is, participants spontaneously initiated risk monitoring visits during the study 
period. 
A common limitation in the sub-studies was the relatively small number of 
participants in each study, which was especially the case in sub-studies III and IV. 
This was primarily due to the lack of willingness to participate in the initial 
screening visit and the considerably high percentages of drop-outs during the 
follow-up. In study I, the application of our test to other populations is limited by 
the fact that the predictive values depended on the prevalence of abnormality in the 
population being tested. In study II, the cross-sectional design of the study limited 
the ability to infer causality between the observed associations. In studies III and 
IV, because we studied Finnish men aged 40 years, caution should be warranted 
when generalising the results to age groups or ethnic groups other than Caucasians. 
Although our study did not include women, the method has been successfully 
applied to middle-aged women for preventive purposes in occupational healthcare 
(228). 
 In 2006, the initial invitation was addressed to all men born in 1966 and living in 
Helsinki. Of this population, 34% accepted the invitation and took part in a 
screening visit. The number of subjects declined further when 47% of potential 
participants invited to a two-year follow-up visit accepted the invitation. 
Subsequently, 41% of potential participants invited to a five-year follow-up visit 
accepted the invitation. These dilutions of potential participants at each stage of the 
study are likely to weaken its strength. In a primary prevention programme in 
England, the National Health Service offered cardiovascular risk assessments to 
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adults aged 40 to 74 years (229). Participation depended on the method of the 
invitation: invitation by a formal letter, 30.9%; invitation by a personalised letter, 
31.3%; and invitation by a telephone call, 47.6%. Participation figures in our study 
were comparable with these. 
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10  CONCLUSIONS AND FUTURE DIRECTIONS 
Various methods can be used to evaluate CVD and diabetes risk profiles starting 
with the WC measurement and proceeding to a complex risk factor measurement or 
lifestyle assessment as well as combinations of these. The significance of the 
identified risk profile depends on the life-cycle phase. The harmful consequences 
of risk factors when found in childhood are more likely to be preventable than 
those observed in older people. In adolescence, the impact of risk factors on the 
circulatory system will be in the future, while in the elderly, some consequences 
may already have been manifested. When risk factors call for intervention in 
middle-age and younger people, mostly at the start, it is a matter of lifestyle 
modification. Among older people, especially among those with a high short-term 
risk in addition to lifestyle changes, often medication is also needed as a prevention 
measure. 
We found that visceral fat is an independent predictor of a cluster of metabolic risk 
factors and that it is strongly associated with WC. Our study also showed that the 
measurement of WC is a feasible screening tool among 40-year-old men to identify 
those who are at increased risk for CVD and/or type 2 diabetes. However, a 
waistline above the cut-off value alone does not provide enough information to 
initiate comprehensive risk communication. Nevertheless, it should trigger a more 
profound risk profile evaluation.  
Regardless of the socioeconomic status and whether the participants continued risk 
monitoring visits, all participants showed improvement in all lifestyle factors 
assessed. Among those with low socioeconomic status and those who neglected 
risk monitoring visits, lifestyle changes were not sufficient to achieve a statistically 
significant overall CVD risk reduction, as among those with higher socioeconomic 
status and those who continued risk monitoring visits. Although the reasons for the 
range of behaviours of the study’s participants during the follow-up period are 
beyond our study’s questions, our observations emphasise the consideration of 
social inequality and stress the importance of easy access to continuous support and 
guidance. 
According to clinical guidelines and good clinical practice, comprehensive CVD 
and diabetes risk assessments should be implemented at the earliest in middle age; 
individual abnormal risk factors and harmful lifestyle habits should be addressed 
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throughout the lifespan. The longer the duration of adverse risk factors or an 
unhealthy lifestyle, the more likely one is to develop CVD, diabetes and other 
related outcomes.  
In the primary prevention of CVD, there are two key issues: to identify individuals 
at risk and to motivate them to maintain lifestyle changes in the long term. Our 
five-year follow-up study showed that, with a practice introduced in Helsinki, a 
favourable outcome can be achieved.  
The screening programme started in Helsinki in 2006, and it has continued in a 
modified form since 2015. In the modified screening method, subjects complete an 
online health check questionnaire. Those with moderately elevated risk are directed 
to take part in appropriate risk management programmes. Those with a high risk 
receive an invitation to the office for a more in-depth investigation. In the modified 
screening method, age and gender are included as risk factors, which enable the 
expansion of the use of the screening method. The internet-based health check, 
including risk assessment, offers an opportunity for more extensive research use in 
the future.  
Alongside the high-risk approach, a population-wide strategy is needed. As means, 
large-scale health education should begin as early as the child welfare clinic and 
continue in schools and other institutions, complemented with related information 
disseminated via the media. Other means include, for example, food labelling to 
make healthy choices easier, tobacco and alcohol taxation, and an environment that 
encourages physical activity. The ultimate goal is to change social norms and 
environments to support healthier behaviour.  
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